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ABSTRACT OF DISSERTATION 
  
 
 
COFILIN NAVIGATES CELLULAR CYTOSKELETON 
 AND INVASION RESPONSESTO TGF-β  
TOWARDS PROSTATE CANCER METASTASIS     
  
   Cofilin’s activity to nucleate actin filament assembly, is regulated by phosphorylation 
at a single site on the amino terminus, Serine 3. Phosphorylation at this site abolishes the 
ability of ADF/cofilin to bind to F-actin and inhibits its severing function. This work 
characterizes the ability of dephosphorylated cofilin (mutation at Serine 3 site) to 
navigate prostate cancer actin cytoskeleton and metastatic properties in response to TGF-
β. TGF-β increased Lim Domain Kinase 2 (LIMK-2) activity leading to cofilin 
phosphorylation and decrease actin filament severing in wild type cofilin (WTCFL) PC-3 
cells. Constitutively active cofilin in Serine 3 cofilin mutants (S3ACFL) promoted 
prostate cancer cell filopodia formation, actin severing and directed TGF-β mediated 
migration and invasion. Co-culture of prostate cancer cells with prostate cancer 
associated fibroblasts induced cell invasion in WTCFL and S3ACFL cells. Active cofilin 
further enhanced the invasive response, even in the presence of a TGF-β-neutralizing 
antibody, implicating the contribution of the microenvironment. Active cofilin led to a 
significant increase in prostate cancer cell metastatic potential in vivo and cofilin 
correlated with metastasis in a mouse model of prostate tumor progression. In human 
prostate cancer, cofilin expression was significantly higher in metastasis compared to the 
primary tumors. Cofilin thus emerges as a regulator of the actin cytoskeleton remodeling 
capable of coordinating the cellular responses to TGF-β towards prostate cancer 
metastasis. Understanding how cancer cells interprete TGF-β signals from the 
microenvironment, is critical for defining the mechanism via which TGF-β function is 
switched from a growth suppressor to a metastasis promoter. Here we show that in 
prostate cancer, TGF-β action is directed by active cofilin enabling actin cytoskeleton 
changes and metastatic behavior. The significant association of cofilin with prostate 
cancer metastatic progression supports its predictive and targeting value in metastasis.  
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CHAPTER I 
 
 INTRODUCTION 
  
 
Normal Prostate Gland Anatomy and Function  
  
   The prostate gland is an endocrine organ, located in the male pelvis, above the anus, 
bellow the urethra and it is composed of glandular and fibromuscular tissue (Figure 1.1) 
(Seisen T. et al.; 2012). The glandular cells are known to secrete the prostate specific 
antigen PSA which have been used for many years for the screening and early detection 
of prostate cancer.  The prostate gland is essential for the process of fertilization, it is 
responsible for the secretion of protein rich seminal fluids and proteases like the prostate 
specific antigen (PSA) that nourishes and protect the sperm (Leissner & Tisell, et al.; 
1979).  These fluids are delivered into the urethra via prostate gland contractions where 
they are expelled with sperm as semen during the process of ejaculation.  
    The prostate gland, develops from the endodermal urogenital sinus (UGS), which is 
derived from the caudal terminus of the hindgut. Embryonic connective tissue known as 
urogenital sinus mesenchyme (UGM) surrounds the embryonic connective tissue. (Cooke 
1991). The growth and development of the prostate gland is dependent on androgens. 
Androgens are mainly produced by the testes although a small amount of androgens are 
known to be produced by the adrenal gland (Yadav N. et al. 2012). Testosterone is the 
most predominant circulating androgen; in the prostate testosterone is converted to 
dihydrotestosterone (DHT) by the enzyme 5α-reductase. Before sexual differentiation of 
the UGS, UGM expresses androgen receptors (AR) in both sexes and thus acquires the 
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capacity to undergo masculine development (Cooke et al. 1991). In response to fetal 
testicular androgens, epithelial buds  are going to emerge from the wall of the UGS, grow 
into the surrounding UGM, and form the lobar subdivisions of the prostate into dorsal-
lateral, ventral, and anterior prostate (Price, 1963, Sugimura et al. 1986 , Kinbara and 
Cunha 1995, Marker et al. 2003). 
   The androgenic effects on prostate development are mediated via androgen receptors 
(AR). The androgen receptor not only plays a critical role in the normal development of 
the prostate but in the process of prostate cancer development (Hodgson et al., 2012). 
This transcription factor regulates the expression of genes that are responsible for the 
modulation of epithelial cell growth, proliferation, survival, and differentiation (Cunha et 
al., 2004, Heinlein & Chang, et al. 2002). Upon steroid binding the AR suffers a 
conformational change which result in the dissociation of cytoplasmic chaperones 
revealing the nuclear localization signal. The steroid bound receptor then translocates to 
the nucleus, where it binds to DNA and interacts with transcriptional coregulators 
regulating the expression of targeted genes (Koochekpour, 2010). The AR is known to be 
expressed at some level in the majority of primary prostate cancers (Peter E. Lonergan, 
Donal J Tindal 2011). Studies have established a relationship between the AR expression 
levels in primary and metastatic progression to advanced castration resistant prostate 
cancer (Hodgson et al., 2012). 
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Figure 1.1 The Anatomy of The Prostate. The prostate, gland is located between the 
male bladder and the penis, in front of the rectum. The urethra runs through the center of 
the prostate, from the bladder to the penis, allowing urine flow out of the body. The 
prostate secretes fluid that nourishes and protects sperm. During ejaculation, the prostate 
transports this fluid into the urethra, were is expelled with sperm as semen.  
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Prostate Cancer Development and Progression 
   Prostate cancer or adenocarcinoma of the prostate is defined as a tumor growing in the 
prostate gland (Figure 1.2). It is the most common form of cancer diagnosed in North 
America (According to the American Cancer Society). The American Cancer Society has 
estimated a number of 238,590 new cases of prostate cancer for 2013. It is also the 
second leading cause of male cancer related deaths in the United States and unfortunately 
29,720 of these patients will die from the disease as a result of metastatic spread to the 
bone. 
   The tissue heterogeneity that characterizes prostate tumors has challenged the 
development of reliable biomarkers for prediction and prognosis of the disease. Today, 
there is a real need for the development of novel prostate cancer biomarkers that will 
translate in better methods for screening, therapeutic approaches and implementing 
prevention strategies. Identification of patients at ‘high risk’ for the development of 
metastatic prostate cancer will allow for the selection of those patients that will benefit 
from aggressive interventions to prevent progression and delay bone metastasis 
(Logothetis et al, 2013).  
   The main risk factor for prostate cancer is age. About 5-10% of prostate cancers can be 
attributed to gene defects, meaning that males with family history are more at risk of 
developing prostate cancer themselves. Although several genes have been identified to be 
involved in prostate cancer, the BRCA1 and BRCA2 genes are associated with having a 
two to five times higher risk (Agalliu, 2009, Castro and Eeles, 2012, Dumitrescu, 2012). 
A third risk factor for the development of prostate cancer is race; being African American 
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males at higher risk of developing prostate cancer than White or Hispanic males 
(Crawford 2003, Browley, 2012). 
    Prostate cancer progresses from prostatic intraepithelial neoplasia into metastatic and 
androgen independent carcinoma (Figure 1.2). The bone is the most common metastatic 
site of prostate cancer with 90% of patients with advanced prostate cancer developing 
skeletal metastasis.  The normal prostate gland is encapsulated by two layers of epithelial 
cells known as the basal and luminal cell layers. As prostate cancer progresses, some 
cancer cells with genetic predisposition and promotion by environmental stimuli, become 
more aggressive, begin to degrade the surrounding double layer of epithelial cells and 
escape into the stroma, triggering a series of molecular events known as the metastatic 
cascade. The next step for this specific set of malignant cells is to directly invade the 
surrounding tissue, or disseminate via lymphatic system allowing the spreading of cancer 
cells, to those organs situated near the prostate such as the neurovascular bundle, penis, 
seminal vesicles, bladder and rectum. The intravasation of cancer cells into the lymphatic 
system result in the systemic spread of cancer cells to distant organs, including the bones, 
lung, and liver. 
Oncogenes and Tumor Suppressors in Prostate Cancer 
   Among the molecular pathways known to be altered in cancer oncogene activation and 
tumor-suppressor suppression are the most common events triggering the initiation and 
progression of most types of cancers, however a relatively small number have been found 
to be implicated in prostate cancer.  Some of the genes found to be altered in prostate 
cancer are the oncogene Myc and the product of TMPRSS2:ETS gene fusions which are 
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often elevated throughout the course of disease progression. In addition, the 
PI3K/AKT/mTOR pathway is commonly activated in prostate cancer due to the loss of 
tumor-suppressor PTEN, while RB activity and/or expression loss have being found to 
promote castration resistant prostate cancer. 
  PI3K activity plays a critical role in the regulation of cell growth and apoptosis. It is 
known that about 40% of primary prostate cancers and 70% of metastatic prostate 
cancers present gene alterations involving the PI3K/AKT pathway such as the loss of the  
PTEN (phosphatase and tensin homolog), encoding a lipid phosphatase that negatively  
regulates AKT activation (El Sheikh et al., 2008). Studies involving homozygous deletion 
of PTEN in mouse models show that the loss of PTEN is sufficient to induce metastatic 
tumors (Wan et al., 2003). However recent data have shown that PTEN deletions in 
mouse knockout models are not sufficient to support progression into metastatic prostate 
cancer, and suggested the involvement of additional molecular mechanisms supporting 
metastatic spread including the AKT PI3K and TGF-β signaling (Bjerke et al. 2013). 
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Figure 1.2 Prostate Cancer Progression. Prostate cancer progresses from prostatic 
epithelial neoplasia into metastatic and androgen dependent carcinoma. As prostate 
cancer progresses, some cancer cells with genetic predisposition and promotion by 
environmental stimuli, become more aggressive, begin to degrade the surrounding double 
layer of epithelial cells and escape into the stroma. 
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Figure modified from: Barron D A, and Rowley D R Endocr Relat Cancer 2012; 19:R187-R204 
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Current Therapeutic Strategies For Prostate Cancer 
   Among the available prostate cancer therapies endorsed by the clinical practice; 
surveillance, radical prostatectomy and external-beam radiotherapy are offered to men 
with clinically localized prostate cancer (Thompson et al., 2007, Heidenreich, 2011). 
Radical prostatectomy and radiation therapy are the most commonly used treatments for 
organ confined tumors with a 10 year survival rate of 60%. However several side effects 
including sexual, urinary and bowel dysfunction can affect the patient quality of life. The 
only treatment conferring improved survival to patients with advanced metastatic prostate 
cancer is androgen ablation therapy. The apoptotic response to androgen ablation is the 
underlying mechanism driving tumor regression and therapeutic benefit in prostate cancer 
patients (McKenzie and Kyprianou, 2006). The majority of prostate tumors recur 
however emerging as castration-resistant, due to prostate cancer cells developing 
resistance to androgen-ablation induced apoptosis.  
    Evolution from androgen dependent to androgen- independent prostate cancer 
(currently known as castration-resistant prostate cancer) is the result of a complex 
interplay of signaling pathways becoming dysfunctional, triggered by an aberrant AR 
signaling (Lonergan and Tindal 2011). Several mechanisms have been proposed to lead 
AR mediated castration resistance such as: 1) AR amplification/overexpression; 2) gain 
of function; 3) intracrine androgen production 4) overexpression of AR cofactors; 5) 
ligand independent AR activation by cytokines and growth factors; 6) constitutive active 
messenger ribonucleic acids (mRNA) splice variants of AR. Molecular studies involving 
immunohistochemical profiling of AR on tumor tissue samples from castration resistant 
patients have shown that  AR is not only highly expressed, but also transcriptionally 
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active (Ruizeveld de Winter et al., 1994, Taplin et al., 1995, Holzbeierleinet al., 2004 ).  
In a similar way, studies in xenograft models also showed an increased in the expression 
of AR and restoration of its activity in those tumors that relapsed after castration 
(Gregory et al., 1998, Chen et al., 2004). These findings, together with studies involving 
RNA interference confirm that AR was still required for growth in castration resistant 
prostate cancer (CRPC). The high levels of androgens in samples from castration 
resistant prostate cancer patients (Mohler et al., 2004, Titus et al., 2005), and compelling  
evidence showing that tumors had increased expression of androgen synthesis enzymes, 
(Stanbrough et al., 2006, Montgomery et al., 2008), implicate a castration resistance 
mechanism, via which tumor cells are responsible for androgen synthesis, leading to the 
reactivation of AR transcriptional activity and prostate cancer growth and progression. 
 
Metastasis and The Tumor Microenvironment 
 
  The process of cancer metastasis is facilitated by interactions between cancer cells and 
the tumor microenvironment (Fang and Declerck, 2013 Jezierska-Drutel, 2013, Astekar 
et al., 2013). These interactions are mediated by growth factors secreted not only by 
cancer cells but from additional components of the tumor microenvironment such as 
immune cells, endothelial cells and fibroblasts (Figure 1.3) (Dutsch-Wicherek and 
Kazmierczak, 2013). The contribution of growth factor secretions by different cell types 
present in the tumor microenvironment enables the optimal conditions for the growth and 
proliferation of cancer cells. For example, it is known that in breast cancer, parathyroid 
hormone-related protein and interleukin (IL)-11, produced by cancer cells, activate 
osteoclasts by the receptor activator of nuclear factor-κB (RANK)-RANK ligand 
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(RANKL) (Morgan et al., 2004). The activated osteoclasts are responsible for the 
induction of bone-derived factors release. The molecular mechanisms responsible for 
prostate cancer bone metastasis are not fully understood. However recent studies have 
shown that the co - culture of LNCaP cells with mouse stromal MC3T3-E1 cells result in 
the induction of osteoblastic differentiation of MC3T3-E1 cells. Furthermore, it have 
been shown that LNCaP cells and BMP-4  can cooperatively induce the production of 
growth factors, such as  fibroblast growth factor (FGF)-2 and epidermal growth factor 
(EGF) in MC3T3-E1 cells, promoting proliferation of LNCaP cells (Nishimori et al., 
2012). These stromal cancer cell interactions were found to not only favor the survival of 
prostate cancer cells, but also induce the differentiation of bone stromal cells in the bone 
microenvironment, facilitating the osteoblastic metastasis of prostate cancer (Nishimori et 
al., 2012). These compelling findings implicate a direct contribution of the bone 
microenvironment in facilitating the colonization of prostate cancer cells into the bone. In 
an attempt to explain this organ specific pattern of metastatic spread not only observed in 
prostate cancer but among different types of cancers, the “seed and soil” theory was 
proposed over a century ago (1889) by Stephen Paget. The theory proposed that there 
was something rich in the metastatic sites that promoted cancer cell growth in a similar 
way that seeds tend to grow in fertile soil, i.e., that factors in the environment at a 
metastatic site contributed to the targeted growth and proliferation of cancer cells. 
(Stephen Paget, 1889, reviewed in Tantivejkul et al. 2004). Today this theory continues 
to be relevant and supported as many factors have been found to be involved in the 
attraction and growth of prostate cancer cells specifically to the bone. As an example 
reflecting the important role of the bone microenvironment in supporting the growth and 
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proliferation of prostate cancer cells, bone extracts are able to induce at least a three-fold 
increase in invasion by PC-3 and DU145 cells compared with brain and other tissue 
extracts, which demonstrates that bone contains significant migration and chemoinvasion 
promoting factors for prostate cancer cells (Jacob et al., 1999).  It is known that more 
than 95% of the bone ECM is composed of collagen type I, however, many other proteins 
are also deposited by osteoblasts during bone for- mation (Hauschka et al., 1986). 
Osteonectin, a glycoprotein known to be secreted by osteoblasts during bone formation, 
has been identified as the chemoattractant responsible for the promotion of prostate 
cancer cell invasion (Jacob et al., 1999). In addition co-culture of PC-3 cells with 
osteoblasts have revealed that TGF-β produced by osteoblasts stimulates PC-3 cell 
migration and invasion as well as increases a2b1 and a3b1 integrins expression (Festuccia 
et al., 1999).   
   The signaling transduction and cell to cell interactions contributing to prostate cancer 
cell proliferation in the bone, are mediated through the engagement of integrin receptors 
since the main component of bone ECM is collagen type I which is a ligand for a2b1 and 
a3b1 integrins. Indeed greater proliferation rates for prostate cancer cells have been 
observed in cells grown on collagen I compared to fibro- nectin substrates; cell signaling 
through phos- phatidylinositol 3-kinase (PI3K) and increased expression of cyclin D1 are 
implicated in this process (Kiefer and Farach-Carson, 2001). Blocking antibodies against 
the avb3 integrins can efectively reduce prostate cancer cell adhesion to crude bone 
protein extract by 94% (Hullinger et al., 1998), suggesting an important role of the 
integrins in the process of bone metastasis. 
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    Aside from the contribution of factors in the bone microenvironment, prostate cancer 
cells themselves are known to be functionally involved in bone remodeling (Chung, 
2003). Prostate cancer metastases are known to have an osteoblastic nature, and evidence 
supports a role of bone morpho- genetic proteins (BMPs) in the course of bone metastasis 
since they contribute to bone formation. In 1992, Bentley et al. reported for the first time 
the expression of BMP-6, a member of the TGF-β superfamily, in prostate tissue samples 
of over 50% of patients with clinically defined metastatic prostate cancer, but not non-
metastatic or benign prostate samples. Overexpression of BMP-6 in metastatic prostate 
cancer cells was confirmed in subsequent studies by, (Barnes et al., 1995; Hamdy et al., 
1997; Autzen et al., 1998; Thomas and Hamdy, 2000). The secretion of BMP-6, among 
other proteins, by prostate cancer cells could explain targeted osteoblastic lesions during 
prostate cancer metastasis since BMP-6 stimulates osteoblastic differentiation of 
pluripotent mesenchymal (Ebisawa et al., 1999). Moreover, osteoblastic differentiation is 
dependent on the activation of focal adhesion kinase (FAK), an immediate effector of the 
integrin signaling pathway (Tamura et al., 2001). 
 
 
 
 
 
 
 
 
15 
 
 
 
Figure1.3 Components of The Tumor Microenvironment. The process of cancer 
metastasis is facilitated by interactions between cancer cells and the tumor 
microenvironment. These interactions are mediated by growth factors secreted by cancer 
and additional components of the tumor microenvironment. The recruitment of 
endothelial cells, immune cells and CAFs facilitates ECM degradation and the escape of 
cancer cells into the stroma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
 
 
 
                                         
 
 
                                                                            Endothelial Cells 
                               Fibroblasts 
STROMA 
                                   
BASEMENT MEMBRANE                                            Immune Cells 
 
EPITHELIUM 
                                 Epithelial Cells                             
                                                                                               Carcinoma Cells 
                                     
Figure 1.3 Components of The Tumor Microenvironment 
 
 
 
 
 
 
17 
 
 
 
TGF-β Signaling in The Prostate Microenvironment 
 
   Transforming growth factor-β (TGF-β) and its signaling effectors are extensively 
studied as critical determinants of tumor cell behavior in the context of the 
microenvironment. This secreted cytokine was originally named from its capacity to 
induce anchorage-independent growth of normal rat kidney cells and fibroblast cell lines 
i.e., to induce transformation (Moses et al. 1981, Roberts et al. 1981). The later discovery 
of its multifunctional roles, not restricted to cell growth regulation, but also involving, 
cell cycle control, differentiation, apoptosis, extracellular matrix formation, angiogenesis, 
and immune functions, proved the name of Transforming Growth Factor Beta to be 
misleading (Bottner et al. 2000, Dunker and Krieglstein et al. 2000, Lawrence et al. 
1996).  
    Three different types of mammalian TGFβ’s have been characterized so far, TGF-β1, 
TGF-β2 and TGF-β3. The most frequently upregulated in tumor cells is TGF-β1 
(Schirmer et al. 2009). TGFβ’s signaling is transmitted through two types of receptors 
(TβRI and TβRII) followed by downstream targeting through regulation of the SMAD 
family of protein effectors. TβRI and TβRII are serine-threonine proteins kinases that 
contain an extracellular ligand-binding domain, a single transmembrane domain, and a 
cytoplasmic serine-threonine kinase domain (Figure 1.4). Type one receptors have a GS 
domain preceding the kinases domain which is phosphorylated during signal 
transduction. Type II receptors have a shorter C-terminal tail at the end of the kinase 
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domain and have also a shorter extracellular domain with different distribution of 
conserved cysteines. During TGF-β signal transduction, type II receptor goes through a 
conformational change upon ligand binding of the extracellular domain and forms a 
complex with the type I receptor which facilitates phosphorylation of the type I receptor 
at its GS domain. Once phosphorylated by TβRII, TβRI phosphorylates the receptor 
activated SMAD proteins (SMAD2 and SMAD 3), which form a heteromeric complex 
with the co- SMAD SMAD 4 and enter the nucleus to activate or suppress target gene 
expression by direct or indirect interactions with promoter regions of specific genes  (Fig. 
1.4). TGF-β signal transduction results in the inhibition of cell entry into S - phase by 
upregulation of cyclin-dependent kinase (CDK) inhibitors (Padua and Massague, 2009). 
A critical event involved in TGF-β mediated growth arrest is induction of expression of 
the CDK inhibitors p15 and p21. Induction of p15 or p21 in response to TGF-β is due to 
SMAD- mediated transcriptional activation. p15 prevents cell cycle progression by 
interacting with complexes of CDK2 and cyclin A or cyclin E and inhibiting CDK2 
kinase activity. The second inhibitor, inhibitor p21 inactivates the catalytic activity of 
CDKs by interacting and inactivating CDK4 and CDK6, or by associating with cyclin D 
complexes of CDK4 and CDK6. Without the action of CDKs and formation of active-cell 
cycle promoters cells cannot progress through the cell cycle.  TGF-β has been shown to 
induce apoptosis in many cell types (Gordon and Blobe, 2008).  
The SMAD pathway is the classical signaling pathway of TGF-β family members 
signaling. Increased levels of SMAD 3 or SMAD 4 induce apoptosis, and dominant 
negative/loss of SMAD 3 protects against cell death (Fig. 1.4). Taken together these 
findings implicate SMAD signaling as the main pathway of TGF-β mediated apoptosis. 
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The proapoptotic genes involved in SMAD signaling have not yet been identified. 
Another pathway involved in this process is down regulation of Bcl-X and activation of 
caspase 3 and 8 (Weinberg 1989). Deregulation TGF-β signaling contributes to 
tumorigenesis by either loss of expression or mutational inactivation of its membrane 
receptors or intracellular effectors, the SMADS. Inactivation mutations in TβRII, SMAD 
2 and SMAD 4, are commonly found in many types of human cancers including, brain, 
lung, breast, ovarian and pancreatic cancer. In most of colon and gastric tumors with 
microsatellite instability, TβRII is inactivated by a functional mutation and in a smaller 
percent for microsatellite stable colon cancers (Myeroff et al. 1995). In many other types 
of human cancers like pancreatic, liver and endometrial cancer with microsatellite 
instability TβR-II mutations are relatively rare (Gille et al. 2001). In the case of breast 
cancer no mutations or structural dysfunctions of TβR-II have been found, but a limited 
receptor expression correlates with loss of TGF-β responsiveness, while TGF-β growth 
inhibition is restored in breast cancer cells by stably expressing TβR-II. TGF-β inhibits 
the outgrowth of carcinomas in situ during the early stages of breast cancer while it 
promotes tumor progression and enhances the ability of cancer cells to metastasize during 
late stages of the disease. (Ghellal et al. 2000).  
In addition to the SMAD mediated signaling there are other known mechanisms by which 
TGF-β can perform multiple functions like for example the ERK, JNK, MAPK, P13 and 
Rho GTPase pathways. Evidence from our laboratory and by others, have established that 
TGF-β signaling can proceed without the principal effectors of the signaling pathway 
SMAD 2 and 4 (Zhu, 2006). Studies involving induced apoptosis in HT58 lymphoma 
cells do not reveal any impac in apoptosis (Teicher, 2007). Moreover a proteomic based 
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approach identified two proteins, prohibitin and cofillin as intracellular effectors of TGF-
β in human prostate cancer cells (Zhu, 2006). 
 
TGF-β A Major Contributor To Prostate Tumorigenesis 
 
    Elevated TGF-β expression in the prostate tumor microenvironment is functionally 
linked to tumor progression by increasing angiogenesis and decreasing immune responses 
(Teicher. et al. 2007). TGF-β has shown pro-oncogenic functions in host immune cells, 
myeloid immune suppressor cells (MISCs) by enhancing their ability to infiltrate tumors 
and promote new tumor vessel formation. Studies using transgenic mice engineered with 
a deleted gene encoding for a TGF-β receptor indicated that TGF-β switch from a tumor 
suppressor to a tumor promoter phenotype could involve the recruitment of MISCs into 
the tumor microenvironment, probably due to increased production of chemokine 
CXCL5 or SDF-1/CXCR4 cytokine system by the tumor cells. 
    In normal prostate cancer cells and prostatic carcinoma cells TGF-β is known to induce 
apoptosis in vitro and in vivo. Our laboratory have recently dissected the contribution of 
TGF-β signaling in the in vivo prostate tumor microenvironment, using the 
DNTβRII/TRAMP transgenic mouse model as a tool for the characterization of the in 
vivo consequences of an inactivated TGF-β1signaling on prostate tumor initiation and 
progression. This work established that a dysfunctional TGF-β1 signaling mechanism 
results in partial loss of the inhibitory effects of TGF-β1 leading to an increase of prostate 
cancer epithelial cell proliferation and angiogenesis thus promoting tumor progression 
(Pu et al., 2009).  
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  The role of TGF-β in the inhibition of epithelial cell proliferation and promotion of 
apoptosis in normal prostate epithelium and in early prostate cancer (Bello- De Ocampo 
and Tindall et al., 2003). The fact that disruptions of TGF-β signaling due to either loss or 
inactivation of its transmembrane receptors or intracellular effectors can lead to prostate 
tumor growth rendered this cytokine to be a potential therapeutic target. 
 The challenge in studying TGF-β as a potential therapeutic agent relies in the ability of 
this cytokine to not only suppress cancer cells growth and proliferation during the early 
stages of cancer, but to promote tumor progression and metastases during the advance 
stages of the disease (Padua et al., 2009). TGF-β increased expression in the tumor 
microenvironment provides an advantage for tumor cell survival, because of the 
angiogenic capacity of TGF-β and its potent immunosuppressive effects, including the 
inhibition of natural killer cells and lymphocyte-activated killer cells. Experimental 
studies with pancreatic cell lines (Panc-1) revealed a significant correlation between the 
level of expression of TGF- β1 and lymph node involvement as well as depth of invasion.  
Increased TGF-β levels support its involvement in the process of epithelial to 
mesenchymal transition (EMT) and enhancement of the ability of invasion of pancreatic 
cancer cells (Yin et al., 2006).  
   Transgenic adenocarcinoma of the prostate mouse model (TRAMP), a  prostate cancer 
transgenic mice harboring the dominant-negative mutant TGF-β type II receptor 
(DNTGFβRII), manifested early malignant changes and subsequently highly aggressive 
prostate tumors at a younger age, compared to control TRAMP+/Wt TGFβRII mice (Pu 
et al. 2009). These prostate tumors exhibited significantly increased proliferation and 
vascularity. An epithelial-mesenchymal transition (EMT)-effect was also detected in 
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prostates of TRAMP+/DNTGFβRII mice, as documented by the loss of epithelial 
markers (E-cadherin and β-catenin) and upregulation of mesenchymal markers (N-
cadherin) ( Pu et al., 2009).  Thus in vivo disruption of TGF-β signaling accelerates the 
pathological changes in the prostate by altering the kinetics of prostate growth and 
inducing EMT. 
    During early stages of tumorigenesis for prostate, breast and colon cancer, TGF-β acts 
as a potent tumor suppressor and has an antiproliferative effect, inhibiting tumor growth, 
but as the disease progresses to advance metastatic stage, there is a TGF-β switch to 
tumor promoter, exerting a proliferative effect, increasing motility and cancer spread. The 
dual role of TGF-β presents a serious clinical challenge in the treatment of many types of 
cancers since TGF-β can dictate the dynamics of the therapeutic response and metastatic 
spread in human cancer. Even though  the therapeutic targeting of TGF-β signaling have 
proven to be very challenging; today neutralizing antibodies and small molecule 
inhibitors against TGF-β  have been developed and implemented in clinical trials. 
However the success of these promising therapeutical agents still relies in the better 
understanding of the functional switch of TGF-β from a tumor suppressor to a lethal 
tumor promoter. 
   Angiogenesis, the formation of new blood capillary networks sprouting from pre-
existing vessels is an important and active process during embryonic development. 
During cancer progression the development of new vasculature nourishes and facilitates 
the growth of primary tumors favoring their progression and metastasis. Under normal 
circumstances of angiogenesis is  active  during embryonic development and growth but 
becomes quiescent at adult stages; however reactivation can occur during wound healing 
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and under different pathological conditions including tumor growth and metastasis. TGF-
β is known to suppress or stimulate angiogenesis in a context dependent manner. The 
main mechanisms by which TGF-β enhances or suppresses angiogenesis is via regulation 
of vascular growth factor (VEGF). In vascular endothelial cells TGF-β can induce 
expression of vascular VEGF via the promotion of fibroblast growth factor FGF-2 which 
upregulate VEGF synthesis (Markowitz et al., 1995). Upon the induction of expression of 
VEGF by TGF-β, VEGF can activate VEGR1 and VEGR2 which are two types of 
tyrosine kinase receptors (Byrne et al., 2005). VEGR2 is involved in endothelial cell 
proliferation and survival while VEGR1 have been implicated in chemotaxis and vascular 
permeability (Gille et al., 2001). Several studies documented a correlation between TGF-
β1 overexpression with enhanced angiogenesis around the tumor mass, leading to an 
increased frequency of metastasis of prostate cancer cells (Roberts et al., 1991). In 
contrast, TGF-β secreted by gallbladder tumors inhibits angiogenesis and reduces tumor 
growth, suggesting its tumor suppressor function (Weinberg, 1989). The biggest 
challenge in understanding this TGF-β “paradox” resides in elucidating those tumorigenic 
signaling pathways by which normal tissue specification become aberrant and which of 
the reciprocal signaling events mediated by TGF-β cooperate to control the 
microenvironment.  Interestingly the majority of TGF-β mutations that lead to a 
dysfunctional TGF-β signaling do not affect primary tumors but can enable cancer cells 
to acquire EMT and invasive characteristics. 
   During the process of oncogenic EMT, clusters of malignant cells, loose their epithelial 
characteristics and acquire self-sustained migratory and highly invasive cell phenotypes. 
Thus EMT is characterized by loss of proteins associated with polarized epithelial 
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phenotype and de novo synthesis of proteins associated with mesenchymal, migratory 
morphology of transitioning cells. As an example, the loss of epithelial proteins such as 
MUC1, E-cadherin, ZO-1, desmoplakins, and cytokeratin 18, in cells of epithelial units 
defines epithelial dedifferentiation. In contrast de novo expression of vimentin is 
correlated with down modulation of epithelial cytokeratins and has been proposed as 
canonical marker of the fibroblastoid state of transitioning cells (Franke et al., 1982; 
Boyer et al., 1989). The specific molecular mechanisms by which TGF-β induces EMT in 
vivo has not been well established, but studies in vitro have indicated to be dependent of 
both, Smad- and no- Smad signaling pathways. Our group demonstrated an epithelial-
mesenchymal transition (EMT)-effect in prostates of TRAMP+/DNTGFβRII mice 
(bearing a mutant nonfunctional TGF-β receptor II), as documented by the loss of 
epithelial markers (E-cadherin and β-catenin) and upregulation of mesenchymal markers 
(N-cadherin) [19].  Thus in vivo disruption of TGF-β signaling accelerates the 
pathological changes in the prostate by altering the kinetics of prostate growth and 
inducing EMT. However, overexpression of the type I TGF-  receptor mutant that lacks 
the ability to bind SMAD2/3 but is capable of activating non-Smad signaling, was 
associated with increased tumorigenicity of the primary tumors, but decreased metastatic 
potential of xenografted breast cancer cell lines (Tian et al., 2003; Tian et al., 2004) . 
TGF-β signals in the same fashion, suggesting that TGF-β signaling may not necessary 
be permanently or constitutively active at each stage of early tumor development, but 
rather it depends on the specific stage of the disease, the tumor cell type and the 
surrounding microenvironment.  
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Figure 1.4. SMAD dependent TGF-β Signaling Pathway. During TGF-β signal 
transduction, type II receptor goes through a conformational change upon ligand binding 
of the extracellular domain and forms a complex with the type I receptor which facilitates 
phosphorylation of the type I receptor at its GS domain. Once phosphorylated by TβRII, 
TβRI phosphorylates the receptor activated SMAD proteins (SMAD2 and SMAD 3), 
which form a heteromeric complex with the co- SMAD SMAD 4 and enter the nucleus to 
activate or suppress target gene expression by direct or indirect interactions with 
promoter regions of specific genes. 
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The Role of TGF-β in Prostate Cancer Metastasis 
   The first and most critical step of tumor metastasis is the detachment of cancer cells  
from the primary tumor and extracellular matrix (ECM) following invasion into the 
surrounding tissue, resistance to anoikis, and migration via a chemoattractive path to a 
metastatic site (Sakamoto and Kyprianou, 2010). A distinct molecular program is 
responsible for the regulation of the adhesion, migratory and invasive properties of 
disseminating tumor cells, all processes impacted by the dynamics of the cytoskeleton. 
Growth factors in the tumor microenvironment have been shown to modulate the 
activation of molecular pathways leading to the remodeling of the actin cytoskeleton. 
Growing evidence suggests that TGF-β reduces tumor cell adhesion, and cooperates with 
ErbB2 receptors to induce migration and invasion. The metastatic phenotype in cancer is 
primarily dictated by ECM degradation and formation, and dramatic changes in cell 
adhesion and mobility of cancer cells (Pardali and Moustakas, 2007). TGF-β can 
modulate such cell- interactions with ECM and several studies have demonstrated that 
TGF-β increases metastatic prostate cancer cell adhesion. TGF-β enhanced cell adhesion 
is mechanistically dependent upon p38 MAP Kinase activity. P38 MAP kinases are 
upregulated by TGF-β an action that modulates TGF-β dependent extracellular matrix 
degradation in osteoblasts (Kleef anf Korc, 2002). The mechanism via which p38 MAP 
kinase regulates TGF-β signaling is believed to be at the level of SMAD activation via 
regulation of SMAD phosphorylation (Markowitz et al., 1995). Induction of p38 MAP 
kinase by TGF-β activates SMAD signaling effectors suggesting a possible mechanism 
for SMAD-dependent regulation of cell adhesion. Our group identified the actin binding 
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protein cofilin to be a SMAD-independent intracellular effector of TGF-β in prostate 
cancer cells (Zhu et al. 2006). 
 
The Actin Cytoskeleton 
   The cellular cytoskeleton is composed of three main types of filaments, actin filaments, 
microtubules and intermediate filaments. While microtubules and actin filaments are 
directly targeted to giving structural support to the cell, intracellular trafficking and 
signaling; the actin filaments are directly responsible for cell movement. Actin is 
essential for cell survival because of its central role in key biological processes such as 
cell division, movement, structural and mechanical support. (Pollard and Cooper, 2009). 
This protein was first isolated from muscle cells and initially thought to be exclusively 
involved in muscle contraction. Accounting for about 5 to 10% of total protein, actin is 
known to be one of the most abundant proteins in all eukaryotic cells (Dominguez and 
Holmes, 2011). At least six different actin genes are known to encode actin in mammals, 
four of these genes are expressed in muscle and two in non-muscle cells.  Three main 
actin isoforms expressed in vertebrates include, three α-isoforms of skeletal, cardiac, and 
smooth muscles and the β- and γ-isoforms expressed in nonmuscle and muscle cells. 
Actin proteins are very similar in amino acid sequence and highly conserved through 
evolution. Compared to eukaryotic cells, yeast have only one single actin gene, although 
90% identical in amino acid sequence to mammalian actin. Some of the studies in model 
organisms including Drosophila (Wagner et al., 2002 and C. elegans MacQueen et al., 
2005) have provided evidence to suggest that actin isoforms have both overlapping and 
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unique cellular functions. Table 1 is a collective summary of studies in mouse models 
with individual actin-isoform knockouts showing the diverse phenotypes indicating 
overlapping and non-overlapping functions between the different isoforms (Hoboken, 
2010). 
The individual actin protein is known as (G) or monomeric actin. Each of these globular 
actin monomers has binding sites that mediates head to tail interactions with two other 
actin monomers generating polymers of actin monomers called (F) or filamentous actin. 
Due to a rotation of 166˚ of each monomer in the actin filament resembles a double –
stranded helix with all the actin monomers oriented in the same direction. Since G-actin 
is not an effective ATPase, whereas F-actin is, the main factor regulating the transition 
between G- and F-actin is nucleotide hydrolysis by F-actin, as the ATP state is more 
stable than the ADP state. Actin monomers join the fast-growing barbed (or +) end of the 
filament in the ATP state, hydrolysis takes place in the filament, and ADP-actin 
monomers dissociate faster from the pointed (or –) end. This mechanism of actin 
polymerization/depolymerization is known as actin filament treadmilling (Figure 1.5) 
(Wegner and Isenberg, 1983, Bravo-Cordero, 2013). 
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                         Table 1. Actin Isoforms - Phenotypes in Mouse Models 
 
 
 
 
 
 
Protein 
ablated Gene Allele 
Transgenic 
rescue Phenotype References 
αskeletal-
Actin Acta1 Null 
 
Pups die by 9 days of age; 
exhibit muscle weakness 
Crawford et al., 
2002 
   
αcardiac-
Actin Full rescue Nowak et al., 2009 
   
γcyto-
Actin Does not rescue Jaeger et al., 2009 
αcardiac-
Actin Actc1 Null 
 
Embryonic/perinatal death; 
disorganized myofibrils Kumar et al., 1997 
αcardiac-
Actin 
  
γsmooth-
Actin 
Partial rescue of lethality; 
hearts defective Kumar et al., 1997 
αsmooth-
Actin Acta2 Null 
 
Viable; defects in vascular 
contractility and blood 
pressure regulation 
Schildmeyer et al., 
2000 
βcyto-
Actin Actb Hypomorph 
 
Embryonic lethal 
Shawlot et al., 1998; 
Shmerling et al., 
2005 
γcyto-
Actin Actg1 Null 
 
Reduced viability; small size; 
progressive deafness 
Belyantseva et al., 
2009; Bunnell and 
Ervasti, 2010 
γcyto-
Actin 
 
Conditional-
skeletal 
muscle 
 
Progressive centronuclear 
myopathy 
Sonnemann et al., 
2006 
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Figure 1.5 Actin Treadmilling Protrusion Model. In a process known as treadmilling, 
actin subunits coming from filament depolymerization at the rear of the cell are recycled 
back into new filaments assembled at the front. It is the continuous assembly of actin 
filaments at the leading edge of cells what generates the protrusive extensions of the 
cytoplasm. 
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Figure Modified From: Nature Reviews Molecular Cell Biology (2013) 
 
Figure 1.5 Actin Treadmilling Protrusion Model 
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Cytoskeletal Actin Remodeling and Cell Movement 
   Among the many critical functions of the cellular actin network cell movement is 
required as early as in embryonic development for the processes of morphogenesis, 
neurite movement in the developing nervous system, chemotactic movement of immune 
cells and wound healing (Gurniak et al. 2005).Without actin remodeling and cell 
movement the development and survival of multicellular organisms wouldn’t be possible 
in any tissue environment. In a process known as treadmilling, actin subunits coming 
from filament depolymerization at the rear of the cell are recycled back into new 
filaments assembled at the front. It is the continuous assembly of actin filaments at the 
leading edge of cells what generates the protrusive extensions of the cytoplasm allowing 
the cell to move and determining the direction of cell movement. The dynamic net of 
actin filaments and its rapid polymerization and depolymerization at the leading and rear 
ends allow the cell to attach to a substrate,   contract its body, push forward and move in 
response to stimuli from the microenvironment (Figure 1.6). (Yilmaz and Christophori, 
2010).                        
   The actin cytoskeleton remodeling network is composed by a series of actin binding 
proteins which cooperatively bind, nucleate, sever, and incorporate new actin monomers 
into new actin filaments allowing the cell to develop specific movement, adhesion, and 
invasion structures such as lamellopodia, filopodia and invadopodia (Figures; 1.6 and 
1.7). Inside the cellular cytoskeleton actin is known to interact with more than 60 actin-
binding proteins (ABPs) which regulates the assembly and disassembly leading to the 
remodeling of actin cytoskeletal networks. Cells extending their leading end depend 
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mainly on the activity of four core actin remodeling proteins: 1) The Arp2/3 complex, 
mediating the initiation of new filaments as branches on preexisting filaments (Pollard 
and Beltzner, 2002); 2) capping proteins which terminate filament growth (Cooper and 
Shafer, 2000); 3) ADF/cofilin severing actin filaments and  promoting branching and 
depolymerization of existing  actin filaments (Bamburg et al. 1999) and 4) profiling 
catalyzing the exchange of ADP to ATP, refilling the pool of ATP actin monomers and 
elongating the filaments (Shluter et al. 1997).  
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Figure 1.6 Cytoskeletal Remodeling and Cell Movement Structures. The dynamic net 
of actin filaments and its rapid polymerization and depolymerization at the leading and 
rear ends allow the cell to attach to a substrate, contract its body, push forward and move 
in response to stimuli from the microenvironment. 
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Figure 1.6 Cytoskeletal Remodeling and Cell Movement Structures 
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Cofilin in Control of Cell Movement 
   Among the key actin remodeling proteins needed for cytoskeletal reorganization at the 
leading edge of moving cells, cofilin have proven to be the main regulator of the actin 
dynamics since de novo synthesis of actin filaments in the cell is not favorable due to the 
instability of actin dimers and trimmers. 
    The binding of cofilin to the ADP- actin filament induces stress to the actin filament, 
changes the twist of the actin filament and promotes severing and disassembly of the 
filament (Bamburg, 1999). Cofilin severing activity on already existing filaments allowed 
free barbed ends for the rapid addition of new actin monomers resulting in the rapid 
growth of filaments and filament branching (Figure 1.7). It is known that the rapid 
polymerization of actin filament on a compartmentalized cell cannot continue without 
rapid depolymerization, thus in moving cells cofilin severing activity is critical for the 
formation of  new actin filaments needed for the development of specific migration 
structures and Bamburg , 2010). Indeed ADF/Cofilin has proven to be an essential 
protein, whose deletion leads to lethal defects in centrosome translocation and cytokinesis 
(Gunsalus et al., 1995),  while in contrast, cofilin overexpression have been shown to 
increase cell movement. (Aizawa et al., 1996). In addition to the promotion of new 
filament polymerization at the leading edge, cofilin is known to promote filament 
branching by providing free barbed for nucleation via the ARP2/3 complex resulting in 
membrane protrusions from which invasion structures such as lamellopodia and filopodia 
are born. In parallel action, cofilin supports contractions at the rear end of the cell 
through focal depolymerization of F-actin and the regulation of actin myosin assembly, 
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by inhibiting binding of myosin II to F-actin. These actin/myosin regulated cell 
contractions at the rear end of the cell are critical to pull the cell forward finalizing the 
cell motility cycle. The multiple roles of this single protein in the control of cytoskeletal 
actin dynamics makes cofilin a critical  modulator of  processes as diverse as biological 
embryonic development and pathologic tumor development and metastasis. 
 
 Regulation of Cofilin Activity 
 
   The function of cofilin is temporally and spatially regulated via three types of 
mechanisms, dephosphorylation of cofilin at Serine 3 residue; the release of cofilin from 
PtdIns (4, 5)P2 and the release of cofilin from cortactin (Mizuno, 2012). Although, the 
binding of cofilin to PtdIns (4,5)P2 inactivates cofilin by sequestering the protein at the 
plasma membrane and the release from PtdIns(4,5)P2 via its hydrolysis by phospholipase 
C (PLC) renders cofilin available for the initiation of actin severing , the activity  status 
of cofilin is directly regulated via phosphorylation and dephosphorylation of a single 
serine residue at position 3 (Arber, 1998).  Cortactin binding comprises an alternative 
mechanism to negatively regulate cofilin’s activity, however this mechanism is known to 
be specific to the development of invasion targeted protrusions such as invadopia 
(Weaver et al., 2006, Buccione et al., 2009, Linder et al., 2011). Phosphorylation of 
cofilin on Ser3 inhibits its binding to G actin (monomeric actin) and F-actin (filamentous 
actin) and severing of the actin filament at the leading edge of migrating cells. Several 
studies have documented differences in the cellular distribution of phosphorylated and 
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non-phosphorylated cofilin; being non-phosphoylated cofilin present in motile and 
invasive protrusions such as lamellopodia and filopodia of epithelial cells and 
phosphorylated cofiin uniformly distributed in the cytoplasm with the exception of the 
leading edge (Bravo et al., 2013). Four kinases have the ability to phosphorylate cofilin in 
vivo, LIM kinase -1, LIM kinase -2, (LIMK1, LIMK2), TES kinase 1 and TES kinase 2 
(TESK1, TESK2) (Moriyama et al., 1996, Arber et al., 1998). LIMKs are known to be 
the dominant kinases involved in the regulation of actin dynamics, while TESKs are 
known to be involved in the process of focal adhesion via integrins signaling (Mizuno et 
al. 2012). The Rho-associated, coiled-coil containing protein kinase 1 (ROCK1), is 
responsible for LIMK-2 phosphorylation and activation. LIMK1 and 2 are activated via 
phosphorylation at Thr508 and Thr505 by several types of kinases including ROCK, 
PAK1, PAK2, PAK4, MRCKα and MAPK-activated protein kinase 2. ROCK1, 
phosphorylates and activates LIMK-2 in response to extracellular stimuli such as 
epidermal growth factor (EGF), leading to cytoskeletal reorganization via the activation 
of the RhoA/ROCK1 signaling pathway (Figure 1.8). Cofilin dephosphorylation at Ser3 
and reactivation is performed  mainly by Slingshot (SSH) phosphatase and chronopin 
(CIN) a phosphatase  recently found to be  specific for cofilin dephosphorylation (Niwa 
et al.,2002, Mizuno et al., 2012). Actin polymerization regulated by cofilin 
dephosphorylation/activation is a convergence point in the intracellular signaling network 
through which extracellular stimuli impact actin cytoskeleton, invasion and apoptosis 
Alterations in cofilin and its signaling modifiers have been reported in invasive breast 
and ovarian cancer (Nishimura et al., 2010). 
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Figure 1.7 Cofilin Severing Activity. The binding of cofilin to the ADP- actin filament 
induces stress to the actin filament, changes the twist of the actin filament promoting 
severing and disassembly. Cofilin severing activity on already existing filaments allowed 
free barbed ends for the rapid addition of new actin monomers resulting in the rapid 
growth of filaments and filament branching. The ARP2/3 protein complex serve as 
nucleation sites for new actin filaments while profilin incorporates actin monomers at the 
growing end of new actin filaments. 
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Figure 1.8 Regulation of Cofilin Activity/Function. The Rho-associated, coiled-coil 
containing protein kinase 1 (ROCK1), is responsible for LIMK-2 phosphorylation and 
activation in response to extracellular stimuli, leading to cytoskeletal reorganization via 
the activation of the RhoA/ROCK1 signaling pathway. Phosphorylation of cofilin by 
LIMK-2 at a specific Serine 3 residue, inhibits cofilin actin severing activity. 
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Cofilin in Cancer 
 
   The critical role of cofilin in the modulation of cell movement and invasion lead to 
studies correlating cofilin activity and cancer. Growing evidence revealed the 
overexpression of cofilin protein, as well as genes encoding key regulators of the cofilin 
signaling pathways in different types of cancers like breast, lung, pancreatic and ovarian 
cancer (Sinha  et al. 1999, Nishimura et al. 2010). As an example cofilin was found to be 
overexpressed in the highly invasive C6 rat glioblastoma cell line, A549 human lung 
cancer cells and human pancreatic cancer cells (Sinha et al., 1999, Gunnersen et al., 2000, 
Keshamouni et al., 2006). Studies in mammary carcinoma cells involving the expression 
of a constitutively active LIMK1 that increases the amount of phospho-cofilin in vivo 
demonstrated the inhibition of actin polymerization and motility in response to EGF, 
confirming the impact of alterations in key regulators of cofiling signaling on cancer cell 
movement (Zebda et al., 2000). Additional studies confirm this phenomenon in various 
cell lines since the overexpression of LIMK1   lead to the inhibition of cell movement in 
neuroblastoma cell lines and Ras-transformed fibroblasts (Sahai et al., 2001, Myer et al. 
2005). In contrast, a dominant-negative LIMK1 results in increased movement in 
neuroblastoma cell lines.  Moreover, in vivo studies demonstrated the metastatic potential 
of orthotopic mammary tumor cell inoculation to be directly related to the functional 
output of the cofilin pathway (Wang et al. 2006). As an example, tumors harboring 
suppressed cofilin activity due to cells in which cofilin pathway activity due to LIMK1 
overexpression exhibited decreased invasion and metastasis and were associated with 
increased survival; in contrast, tumors derived from cells with increased cofilin pathway 
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activity (LIMK dominant negative) showed increased invasion and metastasis and were 
associated with decreased survival (Wang et al. 2006). This evidence suggests a link 
between tumor cell behavior and expression patterns of genes encoding cofilin and key 
regulators of the cofilin pathway and provided a new insight into the interaction of 
cytoskeletal modulators with factors in the tumor microenvironment. However the 
precise mechanisms via which cofilin modulates cytoskeletal remodeling in response to 
stimuli from the tumor microenvironment, and how those signals are interpreted by 
cancer cells are still not well understood. 
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CHAPTER II 
 
 RATIONALE AND SPECIFIC AIMS 
 
Rationale 
 
   Metastasis is the cause of 95% of cancer-related deaths. Cancer metastasis is mediated 
by cellular interactions in response to signals from the tumor microenvironment affecting 
cytoskeletal actin polymerization and depolymerization leading to the modulation of cell 
adhesion, migration and invasion. TGF-β  is known to be highly expressed in the prostate 
tumor microenvironment. This growth factor is the quintessential negative growth factor 
via its ability to inhibit proliferation and induce apoptosis. In addition to TGF-β’s role as 
a tumor suppressor this growth factor is known to switch roles and become a tumor 
promoter at late stages of the disease via the promotion of cell invasion, angiogenesis and 
the modulation of cell adhesion and migration.  
 
   The actin binding protein cofilin is directly functionally responsible for the remodeling 
of actin filaments and filopodia formation toward cytoskeletal reorganization, ultimately 
driving cell motility. Previously, evidence from or group, demonstrated that the small 
actin binding protein and main regulator of cytoskeleton actin dynamics cofilin to be a 
SMAD independent effector of TGF-β’s. Understanding how cancer cells interprete 
TGF-β signals from the microenvironment, is significant for defining the mechanism via 
which TGF-β function is switched from a growth suppressor to a metastasis promoter. 
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Thus, I hypothesized that there is an association between cofilin and prostate cancer 
metastatic progression that may be of significant predictive and targeting value in 
metastasis. Hence, the main goals of my work (presented on this thesis) are the following: 
1) to dissect the molecular mechanisms by which the actin binding protein cofilin 
modulates actin cytoskeleton remodeling in prostate cancer cells , towards cell 
movement, attachment  and invasion towards prostate canncer metastasis, 2) to study 
cofilin as a SMAD independent effector of TGF-β and the effect of the tumor 
microenvironment in cytoskeletal remodeling, cell migration, adhesion and invasion in 
prostate cancer cells. 
 
Specific Aims 
 
Secific Aim 1: Determine the consequences of a mutation in cofilin phosphorylation 
(regulation) site Ser 3 in cofilin expression and phosphorylation and the molecular 
mechanisms by which TGF-β modulates cofilin  activity in prostate cancer (PC-3) cells. 
To  gain a mechanistic insight into the role of cofilin in directing TGF-β responses 
towards cytoskeletal remodeling. This study will pursue the identification of molecular 
players directly involved in cofilin modulation by TGF-β. 
 
Specific Aim 2: Determine the biological function of a mutation at cofilin 
phosphorylation site Ser3 in prostate cancer (PC-3) cells. The effect of a mutation in 
cofilin phosphorylation site on prostate cancer cell migration, adhesion and filopodia 
formation is assessed on WTCFL and S3ACFL PC-3 mutants mimicking the 
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constitutively active form of cofilin; as well as in S3DCFL mutants mimicking the 
constitutively inactive form.  The impact of S3ACFL mutation on prostate cancer cell 
invasion in the presence of CAFs will allow the interrogation of the function of cofilin 
phosphorylation (regulation) in prostate cancer cell migration, invasion and adhesion in 
the context of the tumor microenvironment. This study will investigate the role of the 
tumor microenviroment in the regulation of biological processes targeting the actin 
cytoskeleton afecting prostate cancer progression to metastasis.  
 
Specific Aim 3: Determine the in vivo consequences of a mutation on cofilin 
phosphorylation site and its effect on prostate cancer progression to metastasis. To 
determine the in vivo role of cofilin in prostate cancer metastasis, an experimental 
metastasis assay is performed.  This study will extend and confirm the in vitro studies 
described in Specific Aim 2 and will enable the identification of the impact of cofilin 
S3A mutation on the process of prostate cancer in an in vivo physiologically relevant 
setting. 
 
Specific Aim 4: Determine the value of cofilin expression in prostate cancer metastasis. 
These experiments will evaluate the expression profile of total and phosphorylated cofilin 
in the transgenic adenocarcinoma of the mouse model (TRAMP) and in primary and 
metastatic prostate tumors from the same patient cohort.  
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CHAPTER III 
 
EXPERIMENTAL APPROACH 
 
Cell Lines 
   The androgen independent human prostate cancer cell line PC-3, originally established 
from a patient with bone metastasis and known to be highly tumorigenic and metastatic in 
xenograft models (Kaighn et al. 1979) was obtained from the American Type Culture 
Collection (Manassas, VA). PC-3 cells were cultured in RPMI 1640 medium containing 
2.05 mM L-glutamine, 2 g/liter sodium bicarbonate and 2 g/litter glucose (Invitrogen, 
Carlsbad, CA) together with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml 
streptomycin at 37˚C under a humidified atmosphere of 5% CO2. To test our findings in a 
secondary androgen responsive prostate cancer cell line we used the androgen sensitive 
prostate cancer cell line LNCaP overexpressing the TGF-β receptor II (LNCaPTRII) 
previously generated in our laboratory (Guo et al. 1999). LNCaPTRII cells were cultured 
under the same conditions as the PC-3 cell line. Primary cultures of human prostate 
cancer associated fibroblasts (CAFs) were established from radical prostatectomy 
specimens (from prostate cancer patients). Five distinct primary cultures of human 
prostate cancer associated fibroblasts from prostatectomy specimens were generated. 
Characteristics of CAFs (PCa-Str2-6) were analyzed by western blotting for the 
expression of AR, prostate specific membrane antigen, (PSMA), epithelial markers 
cytokeratin-18 (CK-18) and c-Met and stromal marker α-smooth muscle actin in a 
comparative analysis with human prostate cancer epithelial cell lines (LNCaP, PC-3, 
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DU145).  CAFs were maintained in SCBM CC 3204 (Lonza, Walkersville, MD) at 37˚C 
under a humidified atmosphere of 5% CO2. 
Isolation of Prostate Cancer Associated Fibroblasts (CAFs) 
 Human prostate tumor tissue was severed by a scalpel in multiple small fragments in 
SCGM (SCBM+5%FBS) medium in a tissue culture plate. Culture plate was incubated 
undisturbed for 5-7 days (medium was refreshed). After 1-2 weeks, plates were washed 
with PBS, trypsinized for ~2 minutes to detach only stromal cells. Floating cells were 
collected, centrifuged, and resuspended and cultured in SCGM, incubated for 3 days, 
trypsinized again. The process was repeated in T175 flask. Cells were harvested and 
frozen in multiple vials and stored in liquid nitrogen.  Vials were cultured in SCGM and 
tested for cyto differentiation markers by western blotting 
 
Transfections 
   The S3A cofilin mutant prostate cancer cell line was generated by site directed 
mutagenesis in PC-3 cells. A point mutation targeting Ser 3 phosphorylation site was 
induced by PCR. To mimic a dephosphorylated (constitutively active) form of cofilin 
(S3ACFL mutants), a substitution of a Serine on position 3 to Alanine was generated. 
WT and S3ACFL mutant forms of cofilin were introduced into PC-3 cells via stable 
transfection.  S3D cofilin mutation, mimicking the constitutive phosphorylated (inactive) 
form, was introduced in PC-3 cells via transient transfection. Expression vectors for S3D 
cofilin were generous gifts from Dr. Sergei Krupenko, (MUSC, Charleston, SC). Cells 
were transfected with pXJN-HA/cofilin vector DNA using the Effectene Transfection 
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Reagent (QIAGEN 301425, Hilden, Germany). Cofilin expression was silenced in PC-3 
cells by using the siRNA sequence targeting cofilin codons 64-84. A siRNA containing a 
two single-nucleotide mutation of cofilin sequence (C71G and A73U) was used as 
control.  
 
Cell Viability  
   To assess cell viability we used the MTT assay. Cells (104/well) were seeded into 96-
well plates and incubated in growth medium (24 hrs). After incubation with the MTT 
solution for 4 hrs, and after dissolving formazan crystal absorbance was read at 490nm 
(Bio-RAD 680, USA) and the colorimetric reaction product was quantitated 
spectrophotometrically.  
 
Migration Assay 
   The migration ability of WTCFL and mutants S3ACFL (active form of cofilin), 
S3DCFL (inactive form of cofilin) prostate cancer cells was analyzed via wound assay. 
Cells (104 cells/well) were seeded in 6 well multiwell plates, allowed to grow to 60-70% 
density of cell monolayer and a wound was induced using a pipet tip. After wounding, 
cells were exposed to TGF-β (Recombinant Human TGF-β1, R&D Systems, MN, USA) 
(5ng/ml; 24hrs) in the presence or absence of TGF-β (Human LAP TGF-β1 Antibody, 
R&D Systems, MN USA) neutralizing antibody. The number of migrating cells was 
counted in three different fields, under microscopic examination.  
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Adhesion Assay 
  A subconfluent cell culture of wild type and mutants S3ACFL, S3DCFL PC-3 cells   
was treated with TGF-β (5ng/ml, 24 hrs) at 37ºC. Cells (40,000 cells/well) were seeded in 
6-well plates pre-coated with fibronectin (0-8 μg/ml). After 30 min incubation (at 37ºC) 
non adherent cells were removed and adherent cells were fixed with ice cold methanol 
(5min). The number of cells attached was evaluated in three different fields under 
microscopic examination. 
 
 Fibronectin Coating 
    Fibronectin, Humanplasma (1mg) (Calbiochem) was thaw by placing the vial in a 37˚C 
water bath undisturbed until completely thawed. Pre-warmed, sterile, serum free 16140 
RPMI (Invitrogen) culture medium was added to the solution to a final volume of 20ml to 
yield a fibronectin work solution of 50µg/ml. The fibronectin work solution (1ml) was 
added to each well of a 6 multiwell plate, gently swirling the solution to evenly coat the 
bottom of the well. The plates were incubated at room temperature for 45 minutes to 
allow binding of the fibronectin to the surface of the well. Finally fibronectin work 
solution was removed by tilting the plate and gently aspirating with a sterile pipet. 
 
Evaluation of Cell Invasion 
  (a) Matrigel Invasion Assay: The invasion potential was evaluated using a 
Biocat Matrigel Transwell Chamber (Beckon Dickinson, Franklin Lakes, NJ). Cells were 
seeded into the upper chamber of a transwell insert pre-coated with matrigel in serum-
free medium (50,000 cells/well). After 24hrs non-invading cells were removed from the 
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upper chamber and invading cells were stained with Diff-Quick Solution (IMEB Inc., San 
Marcos, CA).  
(b) Matrigel Cell Tracking:  Human prostate cancer-associated fibroblasts 
(CAFs) and PC-3 prostate cancer cells were independently grown in medium containing 
SCBM or RPMI respectively. SCBM medium containing CellTracker™Green CMFDA 
dye (5μM) (Invitrogen USA) and 1640 RPMI medium containing CellTracker™ Orange 
CMTML (Invitrogen USA), were added to CAFs and PC-3 cells, respectively (45mins). 
The CellTracker™ Green CMFDA labeled cell suspensions of CAFs were placed into the 
inner circle of underside membrane of a Biocat Matrigel Transwell Chamber precoated 
with matrigel. Inserts were placed in 12-wells in Biocat Matrigel Transwell Chambers in 
the absence or presence of TGF-β ligand (5ng/ml). CellTracker™ Orange CMTML 
labeled WT and S3ACFL PC-3 cells were seeded in the upper chamber and after 24hrs 
invading cells were detected using an epifluorescence Nikon Eclipse E600 microscope 
(Nikon, Melville, NY). 
 
In-vitro Co-culture Assay 
   Human prostate cancer associated fibroblasts (CAFs) were grown in the inner 
membrane circle of Biocat Matrigel Transwell Chamber inserts and after 24hrs, inserts 
were transferred in Biocat Matrigel Transwell Chambers in absence/presence of TGF-β 
neutralizing antibody 5ng/ml. Prostate cancer epithelial cells were seeded into the upper 
chamber and after co-culturing for 24hrs invading cells are stained with Diff-Quick 
Solution (IMEB Inc, San Marcos, CA) and visualized under light microscopy. 
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Western Blot Analysis 
  Cell pellets and lung tissue were lysed in RIPA buffer (50mM Tris-HCl, pH7.4, 
1%NP40, 0.25% Na-deoxycholate, 150 mM NaCl, 1mM EDTA, 1mM PMSF, (Sigma 
P8340 protease inhibitor).  Protein (30µg) as a cell lysate or tissue homogenate was 
fractioned by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on gradient gels 
and transferred to Immuno-Blot PVDF membranes. The membrane was blocked with 
0.05% Tween-20 and 5% defatted milk (1hr at room temperature) followed by incubation 
to the respective primary antibodies in the same buffer overnight at 4˚C with gentle 
shaking. After 24 hrs the immunoblot was developed with a secondary antibody 
conjugated to horseradish peroxidase (1hr at room temperature) and proteins bands were 
detected using the ECL plus Detection System (GE, Amersham, UK). The 
chemiluminescent image was captured by autoradiography. The antibodies used were: 
anti-cofilin (1:10,000) (Sigma Aldrich, St. Louis, MO), phospho–cofilin (Ser 3) (1:10,00) 
; anti-LIMK-2( 1:1000) (Cell Signaling, Danvers, MA) and (GFP1:100) (Santa Cruz 
Biotechnology, CA). 
 
Immunoprecipitation Assay  
    For the immunoprecipitation experiments, PC-3 cells were transfected with Flag-
tagged WTCFL, S3ACFL, and T25A CFL, and cells were grown in CSS medium for 
24hrs. Cells were subsequently treated with TGFβ1 (for 6hrs) in the absence or presence 
of MEK inhibitor PD98095. Whole cell lysates were subjected to immunoprecipitation 
with the anti-Flag antibody, and Western blots with the specific antibodies as follows: 
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    Cells were lysed by sonication in RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 1% NP-40, 0.25% sodium deoxycholate, and 1 mM EDTA) supplemented with 
protease inhibitor cocktail, 1 mM PMSF and 10 units/ml of DNase I (New England 
Biolabs). After centrifugation at 21,000  g for 12 min at 4°C, the supernatants/clarified 
lysates were isolated and their protein concentrations measured. Aliquots of the clarified 
lysates (~600 ug of protein each) were then pre-cleared with Protein G Plus/Protein 
Agarose beads (Calbiochem) and 1 ug of normal mouse IgG (Santa Cruz) for 1 h, then 
incubated with anti-acetylated lysine antibody (Cell Signaling) and Protein G 
Plus/Protein (30 μl), 18 h at 4°C. After collection by centrifugation and removal of 
supernatant, the beads were then washed three times with RIPA buffer supplemented 
with protease cocktail inhibitors, 1 mM PMSF and 200 ug/ml ethidium bromide. After 
removal of the final wash, equal portions of RIPA and 2X SDS sample buffer were added 
to the beads and immunoprecipitated proteins were released by heating at 95°C for 5 min. 
Equal volumes of each sample were resolved by SDS-PAGE (8%).  
 
Immunofluorescence Staining 
Cells (7x104cells/well) were seeded in 6-well plates containing a glass cover slit and 
exposed to TGF-β (5ng/ml, 24hrs). Cells were fixed in cover slit by adding ice cold 
methanol-free formaldehyde (15mins), followed by two washes with PBS and 
permeabilization with 2ml of Triton X-100 (0.1% v/v) (5mins). After permeabilization 
cover slits were exposed to Rhodamine Phalloidin  for fluorescent staining of filamentous 
actin (Invitrogen). Cofilin expression was detected by blocking the coverslit on goat 
serum buffer for 1hr followed by incubation with primary rabbit anti-cofilin antibody 
56 
 
(1:10,000) for 24hrs at 4˚C (Sigma Aldrich, St. Louis, MO). Cover slits were 
subsequently removed, washed with PBS and incubated with Alexa Fluor 488 
(Invitrogen) (1hr). Images were processed using a fluorescence Nikon Eclipse E600 
microscope (Nikon, Melville, NY). 
 
Experimental Metastasis Assay 
   The metastatic potential of WTCFL and S3ACFL mutant PC-3 cells was examined in 
vivo by the tail vein injection-experimental metastasis assay. Male nude mice (6-wks old) 
(Harlan Laboratories Inc., Indianapolis, IN) were maintained in sterile cages in pathogen-
free environment. Animal experiments were performed under protocols approved by the 
Institutional Animal Care and Use Committee. GFP labeled WTCFL and S3ACFL PC-3 
106 cells were injected into the tail vein of mice (n=6/cell line). At 4-wks post-
inoculation, lungs were excised and metastatic lesions to the lungs were counted under a 
dissection microscope. 
   Wild type and mutant S3ACFL PC-3 cells were cultured in T-75 flasks.  Cells were 
harvested by triptinization and cell suspensions were submitted to centrifugation (1,000 
RPM, 5 minutes). After centrifugation the supernatant was discarded and 1ml of fresh 
growth medium was added.  A cell suspension containing 106 cells per ml was prepared 
as described above. A total of 1ml of cell suspension was injected into the lateral 
saphenous tail vein as followed: 
(a) Mice were restrained via the injection of the anesthetic (Ketamine, conc. 
100mg/ml) (0.1ml per 10 gm of body weight). 
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(b) Periferal vasodilatation of tail vein was induced by submerging the mouse tail 
into a glass beaker containing warm water (5 minutes). 
(c) The injection area was disinfected with ethanol swipes and tourniquet-like 
pressure was applied to the bottom portion of the tail. 
(d) A 28 ½ gauge needle containing 1ml of cell suspension was injected into the 
vein at a slight angle. 
After injection needle was removed and pressure was applied at injection site. 
 
Preparation of Lung Tissue Homogenates 
  Lung tissue homogenates were prepared as followed: Right and left lungs were 
transferred into a Dounce and Potter-Elvehjem homogenizer containing chilled RIPA 
homogenization buffer (50mM Tris-HCL, pH 7.4,150mM NaCl, 1mM PMSF, 1mM 
EDTA, µg/ml aprotinin, 5 µg/ml leupeptin, 1% Triton X-100, 1% sodium deoxycholate 
and 0.1% SDS). Protease and phosphatase inhibitors were added and samples were 
subjected to freeze-thawing (2cycles) and centrifugated (at 18,300xg, 10 min at 4˚C). 
Supernatants were subjected to Western Blot analysis.   
 
Immunostaining Analysis of Paraffin Embedded Human Prostate Specimens 
Human Prostate Specimens: Formalin fixed paraffin embedded specimens 
of human local and metastatic prostate cancer were obtained from the 
University of Kentucky Cancer Center Tissue Biobank with Institutional 
Review Board Approval. Sections (4µm) were affixed to glass slides, 
deparafinized and rehydrated.  Total cofilin and p-cofilin expression was 
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detected using the following antibodies: (C8736) Anti - cofilin from Sigma 
Aldrich (St. Louis, MO), (3311) Phospho – cofilin (Ser 3) from Cell Signaling 
Technology (Danvers, MA). Palladin expression was detected using (10853-1-
AP) PALLD palladin antibody fom Proteintech Group. E- Cadherin 
expression was detected using (24E10) E-Cadherin rabbit Ab from Cell 
signaling Technology (Danvers, MA). Sections where incubated with the 
corresponding primary antibodies (1:50 to 1:100) overnight at 4ºC). After two 
washes with 1x TBS - 0.1% Triton – X  slide sections were incubated with 
Mollipore (21537) IHC select immunoperoxidase secondary detection system 
(1hr) followed by incubation with Millipore Streptaviding HRP (1hr at room 
temperature). Peroxidase activity was detected by applying Diaminobenzidine 
(DAB) and counterstained with hematoxylin. Slides were analyzed under a 
light microscope followed by pathological evaluation. Images were 
photographed at 40x magnification.  
 
TRAMP Mouse Model: The transgenic adenocarcinoma mouse prostate 
(TRAMP) was used to investigate the correlation between cofilin and 
phosphorylated cofilin expression and prostate cancer progression. TRAMP is 
considered a suitable model of prostate tumorigenesis. As shown below, 
TRAMP transgenic male mice develop prostate cancer from prostatic 
intraepithelial neoplasia (PIN) into metastatic androgen independent 
carcinoma in a manner resembling the clinical progression of human prostate 
cancer patients.     The TRAMP transgene is in the C57BL/6J genetic 
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background. TRAMP mice are transgenic mice that express SV40T/t antigen 
under the prostate specific rat probasin promoter. Tissue sections from (16, 
20, 24, 28 wks) TRAMP prostate tumors of increasingly aggressive stage 
were subjected to immunohistochemical analysis as above. 
 
 
              
Reproduced from: the greenberglab.fhcrc.org  
 
Figure 3.1: TRAMP Mouse Model of Prostate Cancer Progression 
 
 
Statistical Analysis 
 Statistical analyses are performed with GraphPad Prism 5 for Windows (GraphPad 
Software, San Diego, CA). Data are presented as + Standard Error of the Mean (SEM). 
Numerical values are the mean of three independent experiments. Statistical evaluation of 
the data is performed using the Student t test and Two-way analysis of variance for 
multiple comparisons. Significant difference is defined at P value < 0.05. 
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CHAPTER IV 
 
 RESULTS 
 
Cofilin Activity Directs TGF-β Mediated Actin Severing in Prostate Cancer Cells 
   Phosphorylation of cofilin (CFL) on Ser3 inhibits its binding to G actin (monomeric 
actin) and F-actin (filamentous actin) and severing of the actin filament at the leading 
edge of migrating cells. Constitutively active (dephosphorylated) forms of cofilin were 
generated in PC-3 prostate cancer cells by mutagenesis via substitution of a Serine on 
position 3 to Alanine (S3ACFL mutants) and a Threonine to Alanine at position 25 
(T25ACFL mutants). Immunoprecipitation analysis of phosphorylated protein 
associations in response to TGF-β, revealed that the S3ACFL mutation specifically 
conferring cofilin dephosphorylation, promotes its association with actin (enhancing 
filament severing), while the T25ACFL mutation, (impairing Threonine phosphorylation) 
had no effect on the association of p–cofilin with actin (Figure 4.1). Moreover, the 
presence of MEK inhibitor (PD98059) abrogated the TGF-β mediated association 
between p-Erk and cofilin (Figure 4.1). Mutational activation/cofilin dephosphorylation 
(S3ACFL or T25ACFL), or loss of cofilin expression (shCFL) had no significant 
consequences on prostate cancer cell viability (Figure 4.2). The S3A cofilin mutation, as 
expected, abrogated its phosphorylation by LIMK-2, without affecting total cofilin 
expression (Figure 4.3 A); there was a compensatory upregulation of LIMK-2 levels in 
the S3ACFL PC-3 cells compared to wild type cofilin PC-3 (WTCFL) (Figure 4.3 A, 
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Panel A). Figure 4.3 panel B reveals the endogenous upregulation of downstream 
signaling effectors RhoA and ROCK1 induced by the introduction of cofilin mutations; 
both S3DCFL and S3ACFL cells exhibited a significant increase in protein expression for 
RhoA and ROCK1, compared to WTCFL cells. In response to TGF-β, there was a 
transient induction in phosphorylated cofilin within 3 to 6hrs, that was preceded by a 
significant increase in ROCK 1 and Rho A levels, in the WTCFL but not in the S3ACFL 
cells (Figures 4.3, panels C and D).  
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Figure 4.1 Specificity of S3A Active Cofilin Protein Associations in Response to 
TGF-β. PC-3 cells were transfected with Flag tagged WTCFL, S3ACFL, or T25ACFL, 
after growing in CSS medium (24hrs), cells were treated with TGFβ1 (5ng/ml) for 6hrs 
with or without PD98095. Cell lysates (50µg of protein) were subjected to 
immunoprecipitation with anti-Flag antibody, and subsequent Western blotting with the 
indicated antibodies. Actin and phosphorylated proteins p-Erk and p-cofilin show 
enhanced association with WCFL in response to TGF-β. S3A CFL mutation confers 
constitutive dephosphorylation and thus cofilin fails to undergo TGF-β-mediated 
interaction with actin. In comparison, the T25A CFL mutation impairs threonine 
phosphorylation, but has no effect on the phosphorylated cofilin-actin association in 
response to TGF-β. 
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Figure 4.1 Specificity of S3A Active Cofilin Protein Associations in Response to 
TGF-β. 
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Figure 4.2 Effect of Cofilin Mutational Activation or Loss on Prostate Cancer Cell 
Death and Endogenous Cofilin Expresion. Panels A: The effect of a mutation on 
cofilin phosphorylation site Ser3 or cofilin silencing was assessed by MTT assay. Neither 
shRNA silencing of cofilin expression or inducing a mutation on cofilin phosphorylation 
site has any effect on cell viability.  Panel B: endogenous cofilin expression was assessed 
by Western blotting analysis in prostate cancer cell lines: PC-3, LNCaP, DU145 and C4-
2 as well as in the breast cancer cell line MCF7. The androgen independent PC-3 and 
androgen sensitive LNCaP prostate cancer cell lines together with the breast cancer cell 
line MCF7 showed higher levels of endogenous cofilin compared to DU145 and C4-2 
prostate cancer cell lines. 
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Figure 4.2 Effect of Cofilin Mutational Activation or Loss on Prostate Cancer Cell 
Death and Endogenous Cofilin Expresion. 
 
 
   
 
 
 
                       
A. 
 
B. 
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Figure 4.3 Effect of S3A Mutation on Cofilin Phosphorylation Events in PC-3 Cells. 
Effect of TGF-β on cofilin, p-cofilin and LIMK-2 protein expression in prostate cancer 
cells. Panel A, Upregulation of LIMK-2 protein in mutant S3ACFL PC-3 cells. 
Treatment with TGF-β (5ng/ml) increased LIMK-2 and p-cofilin expression in wild type 
PC-3 cells and decreased the expression of LIMK-2 in the S3ACFL cells. Panel B, 
Western blotting indicating elevated RhoA and ROCK1 protein in S3ACFL PC-3. Panels 
C and D, Treatment with TGF-β increased RhoA and ROCK1 levels in WTCFL cells and 
decreased expression of both proteins in S3ACFL cells. GAPDH was used as loading 
control. Molecular weights for individual proteins are shown on the right. 
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Figure 4.3 Effect of S3A Mutation on Cofilin Phosphorylation Events in PC-3 Cells. 
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Active Cofilin Dictates Prostate Cancer Cell Migration and Invasion Responses to  
TGF-β   
   To determine the effect of a mutation in cofilin phosphorylation site on prostate cancer 
cell migration, we assessed the migration ability of WTCFL and S3ACFL mutants 
mimicking the constitutively active form of cofilin; as a functional control, S3DCFL 
mimicks the constitutively inactive form. The S3A cofilin mutation resulted in a 
significant increase in PC-3 cell migration (Figure 4.4). There was a decrease in cell 
migration in the mutant S3DCFL cells (Figure 4.4). As shown on Figure 4.5, treatment 
with TGF-β (24 hrs) led to a significant decrease in cell migration for WTCFL cells; 
functional blocking of TGF-β by the neutralizing antibody, restored migration capacity to 
control levels in WT cells (Figure 4.5). The impact of S3ACFL mutation on prostate 
cancer cell invasion was interrogated in the context of the tumor microenvironment. The 
quantitative data from the invasion assay indicate no significant difference in the invasion 
potential of S3ACFL cells compared to WTCFL PC-3 cells (Figure 4.6). The increase in 
invading cell number in response to exogenous TGF-β, was abrogated by the presence of 
the neutralizing antibody against TGF-β, in both WTCFL and S3ACFL cells (p<0.05). 
   The reactive stroma contributes to prostate cancer progression through the cancer-
associated fibroblasts that facilitate metastasis (Yang et al, 2007; Jung et al, 2013). To 
assess whether the effect of cofilin on prostate tumor cell invasion was TGF-β-dependent 
as mediated from surrounding tumor associated fibroblasts, prostate cancer cell invasion 
was evaluated in in vitro co-cultures. Fluorescent labeled PC-3 prostate cancer epithelial 
cells (red) were co-cultured with labeled human prostate cancer associated fibroblasts 
(green) in the upper chamber of a matrigel pre-coated transwell insert (24hrs) (Figure 4.7, 
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upper panel). As shown on Figure 4.7 (lower panel), only prostate tumor epithelial cells 
invaded the matrigel. There was no significant difference in cell invasion between 
WTCFL and S3ACFL cell lines (but there was a decrease in the S3D mutant cells). In the 
presence of human prostate cancer associated fibroblasts (CAFs) however, there was a 
significant increase in the number of tumor epithelial cells invading, for both WTCFL 
and S3ACFL PC-3 cells. The S3D CFL mutation (phosphorylation) had no effect on 
prostate cancer cell invasion regardless of TGF-β status (Figure 4.7) (lower panel). 
Simultaneous exposure to the TGF-β neutralizing antibody (5ng/ml) resulted in further 
significant increase in the S3ACFL invasion potential (p< 0.004), (while it reduced 
WTCFL PC-3 cell invasion), demonstrating that only active cofilin was able to 
functionally direct TGF-β signaling (secreted by the CAFs in co-cultures) towards 
enhanced invasive behavior while it further increased S3ACFL migration (lower panel). 
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Figure 4.4 Cofilin Activation Status Dictates Prostate Cancer Cell Migration. 
Mutation in cofilin phosphorylation site Ser3 mimicking the constitutively active form of 
cofilin (S3ACFL) significantly increased prostate cancer cell migration compared to 
WTCFL (p<0.03). Prostate cancer cells harboring the inactive form of cofilin (S3DCFL 
mutation) exhibited a significant reduction in migration capacity compared to S3ACFL 
cells (p<0.006). Values shown are the number of migrating cells from two independent 
experiments performed in triplicate.  
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Figure 4.4 Cofilin Activation Status Dictates Prostate Cancer Cell Migration. 
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Figure 4.5 S3ACFL Mutation Enhances Prostate Cancer Cell Migration by passing 
TGF-β. Upper panel, representative images of increased cell migration ability for 
S3ACFL PC-3 cells compared to WTCFL cells (24hrs). TGF-β treatment significantly 
decreased WTCFL cell migration (p<0.0008), but it had no significant effect in S3ACFL 
cells. Loss of TGF-β (in presence of neutralizing antibody) restored the WTCFL PC-3 
cell migration capacity (to control levels), while it increased S3CFL mutant cell 
migration (p=0.005). Cell (Lower panel) cell migration was also analyzed on the 
androgen sensitive prostate cancer cell line LNCaPTRII overexpressing TGF-β type II 
receptor. TGF-β treatment significantly decreased LNCaPTRII cell migration (p=0.0013). 
Loss of TGF-β (in presence of neutralizing antibody) restored LNCaPTRII cell migration. 
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Figure 4.5 S3ACFL Mutation Enhances Prostate Cancer Cell Migration by passing 
TGF-β. 
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Figure 4.6 Cofilin Navigates Invasive Response to TGF-β. The invasive response of 
prostate cancer cells to TGF-β was assessed in the matrigel assay. The mutation on 
cofilin phosphorylation site had no significant effect on PC-3 cell invasion (black 
barographs). In response to exogenous TGF-β, there was an increase in WTCFL PC-3 
cell invasion potential, but not in S3ACFL cells (p=0.03). Loss of TGF-β (by neutralizing 
antibody) led to a significant decrease in the invasion potential for both WTCFL and 
S3ACFL cells (p=0.04 and p=0.004, respectively). (Lower panel) cell invasion was also 
analyzed on the androgen sensitive prostate cancer cell line LNCaPTRII overexpressing 
TGF-β type II receptor. TGF-β treatment significantly increased LNCaPTRII cell 
invasion.  
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Figure 4.6 Cofilin Navigates Invasive Response to TGF-β. 
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Figure 4.7 Co-Culture of S3ACFL PC-3 cells with Human CAFs Markedly 
Enhanced Prostate Cancer Cell Invasion. Panel A .Characteristics of 5 different 
prostate cancer associated fibroblasts CAFs were analyzed by Western blotting (PCa-
Str2-6) in a comparative analysis with human prostate cancer epithelial cell lines 
(LNCaP, PC-3, DU145) for the expression of AR, prostate specific membrane antigen, 
(PSMA), cytokeratin-18 (CK-18), α-smooth muscle actin and c-Met. As shown in lanes 
2-6, only the cancer associated fibroblasts were positive for the expression of the stromal 
marker, α-smooth muscle actin whether only prostate cancer cells were positive for the 
epithelial markers CK-18 and c-Met. Panel B, representative image of fluorescent labeled 
WTCFL PC-3 prostate cancer cells (red) and human cancer associated fibroblasts (green) 
co-culture (1:1) (48hrs). Panel C, matrigel invasion in co-cultures of WTCFL, S3ACFL 
and S3DCFL with CAFs in the presence or absence of a neutralizing TGF-β antibody.  
Quantitative assessment of invading cells indicates that only active cofilin (S3A 
mutation) directs a further increase in TGF-β mediated cell invasion (derived from 
CAFs). In WTCFL PC-3/CAFs, and S3ACFL PC-3/CAFs co-cultures after 24hrs, CAFs 
significantly increased prostate cancer cell invasion for both WTCFL and S3ACFL cells 
(p=0.004 and p=0.007) (lower panel lanes 1 and 2). Continuous secretion of TGF-β by 
the reactive microenvironment (in presence of TGF-β neutralizing antibody), induced a 
further increase in the number of invading S3ACFL cells (p=0.008), while it decreased 
WTCFL cell invasion. Values are the average from two independent experiments in 
triplicate.  
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Figure 4.7 Co-Culture of S3ACFL PC-3 cells with Human CAFs Markedly 
Enhanced Prostate Cancer Cell Invasion. 
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Cofilin Mediates Prostate Cancer Cell Adhesion via Cytoskeletal Remodeling     
   Cell adhesion is directly dependent on cofilin activity and cytoskeletal actin since 
depolymerization and polymerization of new actin filaments is required for filopodia 
formation (Arjonen et al. 2011). We subsequently investigated the effect of S3A mutation 
on prostate cancer cell adhesion to the extracellular matrix (ECM) component fibronectin 
and filopodia formation. The S3A mutation significantly increased cell adhesion to 
fibronectin compared to control WTCFL cells (Figure 4.8). This correlated with 
cytoskeletal remodeling as indicated by fluorescence staining of F actin and formation of 
filopodia (Figure 4.9). Confocal microscopy revealed an increased number of filopodia 
protrusions in S3ACFL PC-3 (arrows) compared to WTCFL PC-3 cells (Figure 4.9). 
High cofilin expression was detected at cell membrane regions populated by filopodia 
(Figure 4.10). Treatment with TGF-β led to a significant decrease in S3ACFL cell 
adhesion (Figure 4.9), and a reduction in filopodia protrusions (Figures 4.9 and 4.10). 
   To determine whether this cofilin co-localization with filopodia is dependent on 
endogenously derived TGF-β from the surrounding prostate cancer associated fibrobalsts 
(reactive stroma), we subsequently profiled the cofilin/rhodamine phalloidin co-
colocalization, in S3ACFL prostate epithelial cancer cells co-cultured with human CAFs. 
As shown on Figure 4.10, cofilin (green) colocalizes with filopodia protrusions (arrows) 
and loss of TGF-β resulted in increased actin/cofilin colocalization (yellow) with 
filopodia protrusions in S3ACFL cells in this reactive stroma-tumor microenvironment. 
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Figure 4.8 Active Cofilin Mediates Prostate Cancer Cell Adhesion via Cytoskeletal 
Remodeling, an Effect Impaired by TGF-β.  The effect of S3A mutation on prostate 
cancer cell adhesion was assessed via cell adhesion assays to fibronectin. S3A mutation 
significantly increased cell adhesion to fibronectin compared to WTCFL control cells 
(p=0.0003). TGF-β treatment led to a significant decrease in S3CFL cell adhesion 
(p=0.0004), but no effect on WTCFL cells. Values shown are the mean (+/-SEM) of three 
independent experiments performed in triplicates. Statistical significance set at a P value 
of p<0.005. 
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Figure 4.8 Active Cofilin Mediates Prostate Cancer Cell Adhesion via Cytoskeletal 
Remodeling, an Effect Impaired by TGF-β. 
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Figure 4.9 S3A Mutation Enhances PC-3 Filopodia Formation. The effect of S3A 
mutation on prostate cancer cells filopodia formation was assessed via Phalloidin staining 
of actin filaments. Active cofilin enhances filopodia formation; representative images of 
confocal microscopy (40x) show increased number of filopodia protrusions in S3ACFL 
PC-3 (arrows) compared to WTCFL PC-3 cells. Treatment with TGF-β (5ng/ml; 24hrs) 
decreased filopodia protrusions in S3ACFL cells. Filopodia were quantitated as we 
recently described (Zhu et al, 2012). Five random fields were examined for each cell line 
and values shown represent the mean +/- SEM from three independent experiments. 
Statistical significance is defined at P<0.01. 
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Figure 4.9 S3A Mutation Enhances PC-3 Filopodia Formation. 
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Figure 4.10 Cofilin Co-localization with Filopodia is Dependent on TGF-β Derived 
from The Surrounding Prostate CAFs (stroma). Images of cofilin/rhodamine 
phalloidin colocalization, in S3ACFL prostate epithelial cancer cells co-cultured with 
CAFs. Cofilin (green) colocalizates with filopodia protrusions (arrows). Loss of TGF-β 
(in presence of neutralizing antibody) resulted in increased actin/cofilin colocalization 
(yellow) and filopodia protrusions in S3ACFL cells. 
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Figure 4.10 Cofilin Co-localization with Filopodia is Dependent on TGF-β Derived 
from The Surrounding Prostate CAFs (stroma). 
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Active Cofilin Enhances Prostate Cancer Metastasis In Vivo 
In the experimental metastasis assay, prostate cancer cells harboring the S3ACFL 
mutation exhibited an increased metastatic ability in vivo, compared to WTCFL cells, as 
determined by the higher number of  lung metastases produced (Figure 4.11). 
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Figure 4.11 Cofilin Constitutive Activation Promotes Prostate Cancer Metastasis. 
Panel A, Male nude mice (n=12) were inoculated with GFP-labeled PC-3 cells (parental, 
WTCFL and S3ACFL) via tail vein injections. Panel B, Metastatic lesions to the lungs 
were assessed at 4-wks post-inoculation. S3ACFL cells generated a significantly higher 
number of metastases compared to control PC-3 cells (p=0.04). Values show the number 
of metastatic lesions to the lung/mouse for each cell line. Western blots of mouse lung 
tissue homogenates and cell lysates indicate the GFP presence in all samples (positive 
control).   
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Figure 4.11 Cofilin Constitutive Activation Promotes Prostate Cancer Metastasis. 
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Figure 4.12 Schematic diagram illustrating the regulatory impact of cofilin on TGF-
β functional switch towards prostate cancer cell migration, invasion and metastasis. 
Under conditions of constitutive active (S3A mutant) cofilin, TGF-β produced by the 
reactive stroma/microenvironment (cancer associated fibroblasts), unable to 
dephosphorylate cofilin confers increased tumor cell aggressive characteristics and 
metastatic potential. 
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Figure 4.12 Schematic diagram illustrating the regulatory impact of cofilin on TGF-
β functional switch towards prostate cancer cell migration, invasion and metastasis. 
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Cofilin Overexpression Correlates with Prostate Cancer Progression to Metastasis 
TRAMP transgenic mice develop prostate adenocarcinoma with increasing age, 
resembling progression of human prostate cancer to metastasis. Analysis of cofilin 
expression during prostate cancer progression in the TRAMP model, revealed an 
association between high cofilin immunoreactivity and tumor aggressiveness with 
increasing age (16-28wks) (Figure 4.13). Quantitative analysis indicated a significant 
increase in cofilin expression in metastatic tumors (28-wks) compared to early stage 
tumors and normal prostate (16-wk WT) (Figure 4.13). Immunohistochemical profiling 
of cofilin in human prostate tissue specimens from a patient cohort with localized and 
metastatic disease to the lymph nodes, indicated a striking increase in cofilin expression 
in metastasis compared to primary cancer in the same patient (Figure 4.14). Characteristic 
images of cofilin immunoreactivity in poorly differentiated prostate tumors and 
metastasis are shown on Figures 4.14A and 4.14B, respectively). There were no 
significant differences in the expression of p-cofilin or palladin proteins between primary 
and metastatic prostate cancer (Figure 4.14, panels C and D).  
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Figure 4.13 Cofilin Profiling in TRAMP Mouse Model. TRAMP transgenic mice 
develop prostate adenocarcinoma with increasing age, resembling progression of human 
prostate cancer to metastasis. Prostate sections of increasing grade and metastatic tumors 
(16-28wks) were profiled by immunostaining for cofilin expression; WT mouse prostate 
tissue (16wks) was used as control. (magnification X40). Quantitative evaluation of 
cofilin immunoreactivity, as determined by the H-scoring, shows a significant increase in 
metastatic tumors from 28-wks old TRAMP mice (p=0.001) compared to early stage 
tumors. 
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Figure 4.13 Cofilin Profiling in TRAMP Mouse Model 
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Figure 4.14 Cofilin Expression Profile in Human Prostate Cancer. 
 Panel A, H&E staining and cofilin immunostaining in serial sections of prostate tumors 
(Grade 3 and Grade 5) from two different patients. A striking increase in cofilin 
immunoreactivity was detected in the higher Grade prostate tumor. Panel B, 
characteristic image of a metastatic lesion to lymph nodes exhibiting intense cofilin 
immunoreactivity, compared to the primary tumor from the same patient (showing 
absence of cofilin expression). Magnification X, Panel C indicates representative images 
of immunostaining for cofilin, p-cofilin, E-cadherin and palladin on primary and 
metastatic prostate cancer. Panel D, quantitative analysis of protein immunoreactivity 
(from Panel C). There was significant increase in cofilin levels in prostate cancer 
metastasis compared to primary tumors (p=0.005).    
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Figure 4.14 Cofilin Expression Profile in Human Prostate Cancer. 
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CHAPTER V 
 
 DISCUSSION  
 
    Cofilin has been previously identified as a Smad independent effector of TGF-β 
apoptosis signaling in prostate cancer cells (Zhu et al. 2006). TGF-β increases LIMK-2 
activity (upregulates ROCK1 and RhoA kinases) leading to phosphorylated cofilin and 
decreasing actin cytoskeleton severing in prostate cancer cells. The present study 
indicates that while TGF-β mediates a striking reduction in the migratory capacity of 
WTCFL PC-3 cells, it fails to exert such an effect in the mutant S3ACFL cells (Fig. 
4.12). As cofilin is unable to be phosphorylated by LIMK-2 (directed by TGF-β) in 
S3ACFL mutants, our findings suggest an alternative pathway via which TGF-β is 
modulating cofilin activity. One may argue that TGF-β signaling does not exclusively 
target modulation of cofilin severing activity, but it rather impairs prostate cancer in the 
early stages of disease progression by putting the “breaks” on cofilin activity 
(phosphorylation status). During the late stages of tumor progression, a mutation 
conferring constitutive activation of cofilin, enables escape from the TGF-β control of 
actin severing, towards enhanced migratory and invasive properties (Figure 4.12). This 
argument supports a sustained role of cofilin as an effector of TGF-β, potentially 
navigating its functional swinging from growth suppressor to a metastasis promoter 
during prostate tumorigenesis. An acquired enhanced motility at an early stage may 
provide S3ACFL mutants the initial input required to escape the primary tumor site, 
reach a nearby vascular tissue, intravasate, travel through the blood stream and 
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metastasize to a distal site. The optimal conditions will sustain colonization and growth 
and will allow prostate cancer cells to invade and proliferate into a secondary tumor. Via 
the secretion of cytokines and growth factors cancer cells now take advantage and 
modulate the new microenvironment to their favor supporting tumor growth and 
progression to metastasis.  The high levels of TGF-β in the prostate microenvironment 
evidences the active tumor stroma dynamics. Cancer cells can secrete  cytokines and 
respond to extracellular signals from the tumor microenvironment, however in response 
to TGF-β,  cancer associated fibroblasts are going to differentiate into myofibroblasts 
which are known to be involved in extracellular matrix degradation facilitating the 
metastatic spread of adjacent  prostate cancer cells. These dynamic interactions between 
cancer cells and the stroma microenvironment (inflammatory cells, vessels, fibroblasts 
and components of the ECM) in turn impact tumor invasion (Desmoulière et al 2004, De 
Wever and Marel 2003).  
   The results, described in this dissertation, support the notion that impairing cofilin 
activity (due to spontaneous mutations on phosphorylation site), is an early event 
promoting cancer cell migration and metastatic spread. The findings also indicate that 
cofilin severing activity towards actin cytoskeletal remodeling and increased prostate 
cancer cell-ECM adhesion and migration is dependent on TGF-β.  Interestingly enough, 
we also report here that cancer associated fibroblasts substantially enhance the invasive 
properties of prostate cancer cells with mutant cofilin (constitutively active), regardless of 
TGF-β deprivation. This evidence provides a proof-of-principle on a direct pro-invasive 
crosstalk between surrounding cancer associated fibroblasts and prostate cancer cells with  
TGF-ß functioning as a tumor suppressor by activating the RhoA/ROCK1 signaling, 
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leading to phosphorylation and activation of LIMK-2.This impairs cofilin severing 
activity, cytoskeletal reorganization and formation of filopodia, decreasing tumor cell 
migration (illustrated schematically on Figure 4.12 ). During prostate cancer progression 
the TGF-ß functional switch from a growth suppressor to metastasis promoter, is 
programmed by activated cofilin that enables actin cytoskeleton remodeling, conferring 
aggressive tumor cell behavior (Figure 4.12).   
   Cancer metastasis is mediated by cell-matrix interactions engaging components of the 
extracellular matrix (ECM), to form adhesion complexes and actin polymerization to 
form cell protrusions to adhere to ECM, directing cell migration. Characterization of the 
actin cytoskeleton dynamics in tumor metastasis will enable a new platform for targeting 
significant protein interactions towards impairing metastatic progression, as well as 
identification of new markers of therapeutic response in advanced diseases. This study 
identified the functional contribution of cofilin to the metastatic process in prostate 
cancer. The results revealed significant differences in actin remodeling proteins, 
migration, invasion and adhesion potential between the wild type and mutant 
(constitutively active) S3ACFL PC-3 harboring a mutant cofilin phosphorylation site. 
S3ACFL conferred an increase in the migration potential compared to wild type PC-3 
cells, suggesting that cofilin regulation is linked to acquisition of an enhanced migratory 
phenotype of prostate cancer cells. Considering that cofilin is directly responsible for the 
remodeling of actin filaments and filipodia formation toward cytoskeletal reorganization, 
ultimately driving cell motility, the finding that neither mutation S3A or T25A had any 
significant consequences on prostate cancer cell invasion might not be surprising. Indeed, 
cell migration relies on the coordinated remodeling of the actin cytoskeleton and leading 
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edge protrusions of moving cells are formed by lamellopodia and filopodia. (Arjoen et al. 
2011). In breast cancer cells, cofilin activation by epidermal growth factor (EGF), leads 
to increased number of actin filament barbed ends.  It is the elongation of barbed ends via 
the polymerization of G actin monomers that generates new actin filaments and dynamic 
filament branching at the tip of the leading edge (Zebda et al. 2000). In this study we 
found a marked increase in filopodia formation in S3ACFL PC-3 cells and lack of actin 
association with constitutively active cofilin, suggesting alterations in cofilin 
phosphorylation/dephosphorylation in prostate cancer cells interfere with its function in 
actin severing. Considering that filopodia can enable not only cell motility, but also 
facilitate attachment to the ECM and to a distal site promoting colonization and 
formation of secondary tumors (Arjonen et al. 2011), our findings support the concept 
that mutational activation of cofilin, besides enhancing cell movement, can also promote 
cell attachment to fibronectin, possibly by remodeling critical cell-ECM adhesion sites 
and regulatory protein associations.   
   This study establishes that constitutively active cofilin results in actin cytoskeleton 
remodeling impacting prostate cancer cell adhesion, migration and invasion in response 
to TGF-β. Cofilin is thus a non-canonical effector of TGF-β signaling, capable of 
coordinating the cellular responses to TGF-β towards metastasis. The significant 
association between cofilin overexpression/activation with prostate tumor invasive and 
metastatic behavior, supports a potential predictive and targeting value for cofilin in 
cancer metastasis.  
   The immunoshistochemical profiling identified a direct association between cofilin 
overexpression and cancer progression to metastasis in the TRAMP mouse model of 
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prostate tumorigenesis. Moreover, my studies demonstrate a significant increase in cofilin 
expression in human prostate cancer metastasis (to lymph nodes), compared to primary 
tumors. Changes in cofilin expression have been reported in other human malignancies 
including colon and ovarian cancer (Wang et al. 2007, Sadako et al. 2010, Popow et. al 
2012). Loss of the epithelial marker E-cadherin is associated with a more invasive 
phenotype in prostate cancer cells and high grade and metastatic prostate cancer, as 
previously established (Umbas et al. 1992). In addition immunohystochemical profiling 
of total cofilin in tissue microarrays (TMAs) from breast and colon cancer showed high 
levels of expression of total cofilin supporting again, a potentially significant vale for 
cofilin as a biomarker not only for prostate cancer but for different types of cancers. 
Ongoing studies in collaboration with Dr. Andre Balla at the University of Illinois, 
include the profiling of total cofilin and phosphorylated cofilin in TMAs from a larger 
prostate cancer patient cohort with advanced disease. 
   We should consider the involvement of additional actin binding proteins acting together 
to facilitate actin cytoskeletal remodeling since cofilin severing activity is not sufficient 
to support the novo synthesis of actin filaments at the leading edge of moving cells. 
Without actin nucleation by the Arp2/3 complex, the presence of actin bundling proteins 
and the addition of actin monomers by profilin, cytoskeketal remodeling will not 
progress. We found an increase in the actin bundling protein palladin together with 
cofilin in metastatic human prostate cancer specimens compared to primary prostate 
cancer from the same patient, supporting the role of additional actin remodeling proteins 
in the progression of prostate cancer towards metastasis. Since CAFs, or activated 
fibroblasts present in the stroma surrounding solid tumors are capable to promote 
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invasion and metastasis of cancer cells, the mechanisms regulating the activation of the 
fibroblasts and the initiation of invasion are of great interest. Interestingly, the 
upregulation of the cytoskeletal protein, palladin, has been found to be upregulated in 
stromal myofibroblasts surrounding many solid cancers and in expression screens for 
genes involved in invasion. Studies involving a pancreatic cancer model, investigated the 
functional consequence of overexpression of exogenous palladin in normal fibroblasts in 
vitro and its effect on the early stages of tumor invasion. These studies demonstrated that 
that palladin expression can impart myofibroblast properties, in turn promoting the 
invasive potential of these cells with invadopodia-driven degradation of extracellular 
matrix (Brentnall et al., 2012). Additional elegant studies, have confirmed that the 
conversion of fibroblasts into active cancer associated fibroblasts also called 
myofibroblasts, not only is induced by TGF-β, but also involve an increase in the 
expression of palladin (Rönty et al. 2006). The secretion of extracellular proteins, 
proteases, cytokines, and growth factors by myofibroblasts results in the modulation of 
the ECM (Powell et al., 1999; Tomasek et al., 2002). We can consider a scenario in 
which TGF-β in the tumor microenvironment mediates the upregulation of palladin not 
only in tumor associated fibroblasts favoring their conversion into myofibroblasts and the 
degradation of the ECM but also the upregulation of palladin in cancer cells. 
Upregulation of the actin bundling protein palladin, together with an upregulation of 
cofilin severing activity, may provide prostate cancer cells with enhanced actin 
remodeling activity facilitating their escape into the stroma, once the ECM barrier have 
been disrupted by active myofibroblasts. While TGF- β’s role in myofibroblastic 
differentiation have been widely studied, the signaling pathways involved in cytoskeletal 
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modulation are not well characterized. My work identified for the first time that TGF- β 
induced expression of palladin and cofilin is regulated via signaling pathways targeting 
cytoskeleton remodeling in prostate cancer cells. These results are of high clinical 
significance since the use of biological markers for better prognosis and treatment of 
prostate cancer patients relies on the identification of specific proteins correlating with 
metastatic potential. The immunohystochemical analysis for the expression of cofilin in 
primary human prostate cancer tissue together with the actin bundling protein palladin 
and the presence of active myofibroblasts via α-SMA staining have the potential to be 
exploited as a novel and patient specific tool for predicting prognosis in prostate cancer 
patients. The overexpression of unphosphorylated (active) cofilin, together with the 
overexpression of palladin and the presence of activated fibroblast at the primary tumor 
can be used as a marker for prostate cancer metastatic burden. Therefore, I am proposing 
the development of a novel screening technique involving not only the screening for 
prostate specific antigen PSA at early stages of prostate cancer but in combination with 
cofilin, palladin and α-SMA biomarkers. This technique will supplement PSA screening 
and allow to better predict which patients are at higher risks of developing metastatic 
prostate cancer and will require a more aggressive treatment. Indirect support for this 
approach is gained from recent evidence correlating cofilin expression with ovarian 
cancer progression, and a longer progression free survival in low cofilin patient cohort 
(Nishimura et al. 2011) together with findings showing that paladin is overexpressed in 
the CAFs of several tumor types including pancreas, breast, lung, kidney, and ovary but 
is expressed at lower levels in normal stromal fibroblasts (Goicoechea et al., 2010, Ronty 
et al., 2006). 
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   In addition to the potential use of cofilin as a potent biomarker for predicting prognosis, 
the use of cancer specific RhoA and ROCK1 kinase inhibitors for the temporally 
regulation of cofilin severing activity will allow to inhibit prostate cancer metastatic 
spread at early stages of the disease without compromising the overall cofilin activity 
which is necessary for the survival and growth of non-cancer cells. Via the inhibition of 
RhoA and ROCK1 kinases at early stages of the disease in mutant cancer cells, cofilin’s 
phosphorylation by LIMK in response to TGF-β is blocked, suppressing cofilin enhanced 
severing activity and the development of an enhanced migratory phenotype thus 
suppressing metastatic spread. Our results revealed a suppression of the RhoA/ROCK1 
signaling pathway in the wild type cells, however mutant S3ACFL being unable to be 
phosphorylated by LIMK in response to TGF-β were able to escape its tumor 
suppression. Another therapeutic approach based on our results would be the use of 
genetic screening to determine patients with mutations in cofilin phosphorylation site 
predisposing these patients to an aggressive cancer due to the loss TGF-β tumor 
suppression at early stages of the disease. This approach would allow a better 
understanding of prostate cancer dynamics at early stage of disease for each individual 
patient and will translate in the development of personalized treatment depending on the 
genetic background, in terms of cofilin mutations that could facilitate cell motility and 
adhesion to the ECM, together with mutations regulating intercellular adhesion, such as 
like E-Cadherin and N-Cadherin, as well as cytoskeletal ECM linking proteins such as 
integrins. 
   An insight into each of the steps preceding metastatic spread reveals a common 
denominator for the majority of primary solid tumors; the loss of cell to cell adhesions, 
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detachment from the basement membrane and the acquisition of an enhanced migratory 
phenotype; each of these events being directly dependent on cytoskeletal changes and 
ECM remodeling. It is not surprising for the cell cytoskeleton to play such important role 
in the determining the fate of cancer since it comprises the most extended network for 
communication between signaling proteins inside and outside a cell. It is the constant 
traffic of signals facilitated by motor proteins such as Dynein through the cell 
cytoskeleton what facilitates cell movement in any tissue environment. Although many 
efforts focused on the tumor suppressor and oncogenic pathways in cancer allowing 
specific cell types to undergo malignant transformation, we must always recognize that 
most of prostate cancer patients do not die from primary tumors and less attention have 
been directed to the cytoskeletal changes allowing cancer cells to undergo metastasis 
spread. Our focus on the main regulator of the cytoskeleton dynamics cofilin allow us to 
explore many alternatives to not only block the overall migratory potential of prostate 
cancer cells but the transport of signaling proteins and the transduction of signaling 
cascades that facilitates the process of cancer metastasis. One of the possibilities includes 
as discussed before, targeting cofilin activity for the suppression of cancer migration at an 
early stage, however another possibility includes the regulation of cofilin severing 
activity spatially for the delivery of specific therapeutically agents along the cytoskeletal 
network.  By modulating the activity actin binding proteins like cofilin and palladin we 
can attain the selective remodeling of the cellular actin network to our advantage, the 
same way cancer cells remodel the cytoskeleton to obtain an enhanced metastatic 
potential. Therapeutically this will translate into the possibility to selective transport 
drugs such as small molecular inhibitors to specific targets inside the cell or to block 
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signaling molecules like transcription factors from reaching their targeted genes many of 
them tumor promoter genes and oncogenes promoting tumor progression.  
   One of the most important candidates for this therapeutic technique based on 
cytoskeletal modulation and transport would be the AR. Via the disruption of nuclear 
actin network in the same way microtubule-targeting drugs, such as the Vinca alkaloids 
and taxanes, have been used to target the mitotic spindle checkpoint, arresting cell cycle 
progression leading to apoptosis it could be possible to attack castration resistant tumors 
via the disruption of AR translocation into the nucleus. To support this idea, previous 
studies from our group comparatively analyzed TMAs from Docetaxel-treated and 
untreated prostate cancer patients for prostate specific antigen (PSA) and AR 
immunoreactivity. The study revealed that in addition to blocking cell division, the 
microtubule stabilizing drug Docetaxel impairs AR translocation into the nucleus (Zhu et 
al., 2010). Although it is clear that microtubules and actin cytoskeleton have distinct 
roles, there have been studies that evidence an interaction between these two, moreover it 
have been found that an intact microtubule cytoskeleton is needed to maintain the 
polarized distribution of actin protrusions at the leading edge of migrating fibroblasts 
(Vasiliev et al., 1970). Thus the targeting microtubules/actin interactions emerges as a 
novel therapy not only for the suppression of  cancer cell movement and progression to 
metastasis but for the delivery of drugs into the cell without affecting overall toxicity and 
overcoming drug resistance via the modulation of signaling cascades routes. The best 
evidence supporting the interactions between the microtubule and actin network is 
provided by the Rho family of GTPases, which can regulate both actin filaments and 
microtubules (Wittmann and Waterman, 2001). Based on our results we can propose a 
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mechanism in which RhoA can suppress the actin polymerization while promoting the 
stabilization of microtubules at the same time via the activation of ROCK1 kinase 
resulting in the phosphorylation of cofilin and the inhibition of actin filaments which in 
turns help stabilize the microtubule network. Thus, we can submit the notion that the 
activity of RhoA is regulated in the same time by microtubules and actin. The activation 
of cofilin severing activity and actin polymerization will promote RhoA/ROCK1 leading 
to phosphorylation of cofilin and the inhibition of actin polymerization resulting on 
microtubule stabilization. Microtubule stabilization will inhibit RhoA /ROCK1 in a 
negative feedback reactivating cofilin severing activity. By transiently inhibiting 
RhoA/ROCK1 we can stimulate cofilin activity, stabilizing microtubule and altering the 
microtubules tracks required by protein effectors for the transduction of signaling 
cascades (Figure 5.1).  
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Figure 5.1 Potential Mechanism for Microtubule Stabilization and Transcriptional 
Inhibition via Targeting of Cytoskeletal Remodeling. RhoA activation suppresses 
actin polymerization while promoting microtubules stabilization at the same time via the 
activation of ROCK1 kinase resulting in the phosphorylation of cofilin and the inhibition 
of actin filaments which in turns help stabilize the microtubule network. Microtubule 
stabilization results in the inhibition of signaling molecules and transcription factors from 
reaching their targeted genes leading to tumor suppression.  
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    Cell to cell communication also play critical role on cancer progression. A collection 
of cell surface proteins recognize signals from the microenvironment and nearby cells. 
Filopodia structures not only are rich in cell adhesion proteins, they are responsible for 
probing the pericellular environment for chemotactic factors and other molecular signals 
in the ECM that enable and direct the movement of the cell and for receiving and 
transmitting information between cells the same way dendrites are used by neuronal cells 
to receive and conduct the electrochemical stimuli from other neural cells inside the brain 
(Horace, 2011). This work demonstrates that the modulation of cofilin actin severing 
activity affects the development filopodia protrusions of prostate cancer cells, a 
significant discovery, since cells utilize filopodia to communicate within the tumor 
microenvironment towards metastasis. Our results demonstrated that a mutation on 
cofilin phosphorylation site (S3A) can enhances filopodia protrusions bypassing TGF-β 
tumor suppression. This study reveals for the first time that cytoskeletal changes impact 
the ability of prostate cancer cells to recognize signals from the tumor microenvironment.  
Proteomics studies performed in collaboration with Dr. Haining Zhu, demonstrated an 
overexpression of EMMPRIN (extracellular matrix metalloproteinase inducer) in the cell 
surface of prostate cancer PC-3 cells compared to benign BPH-1 (Zhu. et al, 2011). 
EMMPRIN silencing markedlyimpaired cancer cell adhesion and filopodia formaton. 
One may consider that the overexpression of EMMPRIN result as cancer cells develop a 
more aggressive and motile phenotype and develop filopodia. Each filopodium serves as 
a template for the cell surface protein EMMPRIN to be exposed to be recognized by 
nearby cells recruiting cells bearing the EMMPRIN receptor on the cell surface in the the 
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same way as immune cells are recognized  by and communicate with  antibodies in the 
circulation by exposing their epitopes at the cell surface (Figure 5.2).  
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Figure 5.2 Role of Filopodia in Tumor Microenvironment Signal Recognition and 
Transduction.  The development of filopodia structures in cancer cells provides a 
template for the cell surface protein EMMPRIN to be exposed and be recognized by 
nearby cells, recruiting cells expressing the EMMPRIN receptor to the tumor site. 
Recruitment of ECM remodeling cells like CAFs, leads to ECM degradation and tumor 
invasion. 
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   What is more, the EMMPRIN interaction with its receptor on target fibroblasts, is 
known to upregulate MMP-1 (matrix metalloproteinase 1) transcription facilitating tumor 
invasion and metastasis (Sidhu et al., 2004). Consistent with these findings we have 
shown enhanced invasion of prostate cancer cells in the presence of cancer associated 
fibroblasts. By targeting cofilin severing activity and cellular cytoskeleton remodeling we 
can impair the development of filopodia on tumor cells inhibiting EMMPRIN exposure, 
the recognition by cancer associated fibroblasts and their recreation to the tumor site, 
therefore inhibiting ECM degradation, tumor invasion and metastasis. What is more, 
studies have demonstrated that therapeutic treatment of pancreatic cancer that reduces the 
cancer-associated fibroblasts is more effective in prolonging survival than standard 
chemotherapy that targets only the cancer cells (Olive et al., 2009, Sahai, 2010, Xu et al., 
2010). Thus deviating signaling cascades to inhibit the recruitment of fibroblast to the site 
of cancer via the modulation of cytoskeletal remodeling, can be exploited as a pre - 
chemotherapeutic treatment to prolong patient survival. The above therapeutic approach 
will change the way we look at and treat cancer today. Since 1889, the seed and soil 
theory has proposed that the presence of factors in specific organ are responsible for the 
growth of only certain types of cancers. Based on my findings, I proposed a new 
hypothesis in which there is not the presence of unique factors in the site of metastasis, 
that promote selective metastatic spread to a specific organ but, the ability of cancer cells 
to receive, transduce and alter signaling pathways on nonmalignant cells in the new 
tumor site. Once cancer cells has taken control of the new microenvironment they can 
signal non-malignant cells to secrete growth factors and immunosuppressive cytokines 
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needed by cancer cells to grow and proliferate on a foreign environment. This study 
proposes that the future of cancer therapy, could rely on 
the targeting of molecular pathways leading to the development of specific signaling 
structures such as the cofilin signaling pathway to block filopodia structures and the 
target of cell surface signaling proteins like EMMPIRIN. Thus by blocking the ability of 
cancer cells to recognize, transduce and deliver signals to the tumor site, we should be 
able to indirectly block, not only the process of EMT, ECM degradation and invasion, 
intravasation into circulation at early stages but the recruitment of blood vessels via 
stimulation of VEFG, and responses to growth factors stimuli like TGF-β on already 
established tumors, changing the fate of tumor cells to die rather than grow and 
proliferate.  
 
Clinical Significance 
    For many years, prostate specific antigen (PSA) screening have saved many lives, 
since it translated on early prostate cancer detection and treatment. However many times 
it has also led to over-diagnosis and overtreatment of prostate cancer patients (Etzioni et 
al., 2012). Another critical problem about the use of PSA is the limited predictive 
accuracy for predicting outcomes after treatment and for making clinical decisions about 
the type and intensity of therapies. Although Gleason Score information have been used 
by pathologists to understand how a particular case of prostate cancer can be treated and 
patients likely to survive following a diagnosis of prostate cancer,  this approach is based 
exclusively on the architectural pattern of the glands of the prostate tumor, does not 
provide information on therapy selection and does not count with a mechanistic 
117 
 
foundation that can guide the best sequences or combinations of agents in targeting 
specific biomolecules. As a result, patients are currently grouped by clinical stage or 
treatment status as:  with or without bone metastasis, resistance to androgen ablation 
therapy or not, with or without chemotherapy (Logothetis et al. 2013). Even though the 
patient's Gleason score with his PSA level and the clinical stage estimated by the 
physician can be used to estimate the likelihood that that patient has localized or locally 
advanced prostate cancer of different types, there is an imperative necessity for new 
molecular markers that define a specific stage of progression for the selection of the 
appropriate therapeutic approach independently of tumor stage. This work represents a 
whole new era of prostate cancer screening and management, taking in consideration a 
panel of biomarkers including, genetic background, protein expression at the molecular 
level to predict prognosis and therapy selection as well as the targeting of the 
communication network between biological components and the active tumor 
microenvironment. All of this valuable information will supplement the use of PSA and 
Gleason Scoring and will lead to a better understanding of prostate cancer that will be 
used to attain sufficient degree of certainty that would guide the best clinical decisions 
based on individual patients.  
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Future Directions 
   In order to understand the role of cofilin in normal prostate epithelial cells, a mutant 
S3ACFL, benign prostate hyperplasia (BPH) cells line will be generated via stable 
transfections and migration, invasion and cell adhesion ability will be compared between 
wild type and mutant cofilin BPH cell lines.  
   To examine if TGF-β signaling is required for the suppression of prostate cancer 
metastasis on mutant S3ACFL and WTCFL PC-3 cells at the physiological level, the 
double transgenic DNTβRII/TRAMP mouse model bearing a dysfunctional TGF-β type 2 
receptor will be injected with wild type and mutant cofilin PC-3 cells via tail vein and 
metastatic lesions to the lung will be analyzed. This study will allow to characterize the in 
vivo consequences of an inactivated TGF-β signaling on mutant S3ACFLand WTCFL 
PC-3 cells progression to metastasis. The results will show if a dysfunctional TGF-β 
signaling mechanism results in loss of the inhibitory effects of TGF-β leading to an 
increase of prostate cancer epithelial cell metastatic potential. 
   As a secondary model of tumor metastasis, we will use an orthotopic implantation 
model of human prostate cancer with the purpose of mimicking closer some of the 
characteristics of human cancer metastasis. This model consist on the direct implantation 
of PC-3 cells into the ventral lobe of the prostate of athymic mice allowing tumors to 
progress for 4 to 6 weeks. At experiment termination, several distinct endpoints will be 
measured, such as size and molecular characterization of the primary tumor in terms of 
total and phosphorylated cofilin expression, the presence and quantification of circulating 
tumor cells in the blood and bone marrow, and number of metastatic lesions to the lung. 
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  To further investigate the role of cell surface plasma membrane proteins in the process 
of prostate cancer metastasis, we are also interested in the development of a double 
transgenic TRAMP/EMMPRIN knockout mice, to elucidate the effect of loss of the cell 
surface protein EMMPRIN in prostate cancer progression to metastasis.  
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APPENDIX 
 
 
 
LIST OF ABBREVIATIONS 
 
AR- androgen receptor 
ATP- adenosine triphosphate 
BPH- benign prostate hyperplasia 
CDKs- cyclin dependent kinases 
CFL- Cofilin  
CRPC- Castration resistant prostate cancer 
DAB- Diaminobenzidine 
CAFs- Cancer Associated Fibroblasts 
CFL- Cofilin 
DNA- Deoxyribonucleic Acid 
DNTGFRII- Dominant negative Transforming Growth Factor Beta Type II Receptor 
EMMPRIN- Extracellular Matrix Metalloproteinase Inducer 
ECM- Extracellular Matrix 
EDTA- Ethylenediaminetetraacetic acid 
EGFR- Epidermal growthfactor receptor 
EMT - Epithelial to Mesenchimal Transition 
ECM - Extracellular Matrix 
EDTA - Ethylenediaminetetraacetic acid 
FGF- Fibroblast growth factor 
GFP- Green Fluorescent Protein 
LIMK- Lim domain kinase 
MAPK- Mitogen- activated protein kinase 
MTT- (3-(4,4,5-Dimethylthiazol-2-yl)-2,5)-diphenytertazolium bromide 
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PCR- Polymerase Chain Reaction 
PBS- Phosphate Buffered Saline  
PI3K- Phosphatidylinositide 3-kinases 
PMSF- Phenylmethanesulfonylfluoride  
PSA- Prosta Specific Antigen 
PTEN - Phosphatase and tensin homolog 
RANKL- Receptor activator of nuclear factor kappa-B ligand 
RIPA- Radioimmunoprecipitation Assay Buffer 
ROCK1- Rho-associated, coiled-coil containing protein kinase 1 
SDS- PAGE - Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SHH- Slingshot phosphatase 
TGF-β- Transforming growth factor beta 
TMPRSS2- Transmembrane protease, Serine 2 
TRAMP- Transgenic adenocarcinoma of the mouse prostate 
UGM- Urogenital sinus mesenchyme 
UGS- Urogenital sinus 
VEGF- vascular endothelial growth factor 
VEGF- vascular endothelial growth factor receptor 
WT- wild type 
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